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Abstract 
Respiratory virus infections are a major cause of morbidity and mortality worldwide. 
Decades of research have yielded many breakthroughs in our understanding of 
virus-host interactions, but many aspects of viral pathogenesis still remain 
unresolved. Vaccines and antiviral treatments have been developed, but they are 
imperfect or completely lacking for many viral agents. Novel emerging viruses form 
an additional challenge, which can only be overcome by proper preparation and 
quick response against these unexpected infectious threats. Understanding virus-host 
interactions is critical for elucidating aspects of viral pathogenesis and devising 
better treatment strategies against viral pathogens. 
 
Our research has focused on the virus-host interactions of two major respiratory 
pathogens with a recent history of outbreaks by a novel viral agent, the influenza A 
virus and coronavirus. Influenza A virus has plagued humankind throughout human 
history and continues to cause annual epidemics and occasional pandemics 
associated with significant mortality. NS1 protein is one of the major virulence 
factors of influenza A virus. It has a multitude of different interactions with host cell 
components that either aid viral replication or hamper the antiviral response 
exhibited by the host cell. These interactions are located both in the host cell nucleus 
and the cytoplasm, and three signals regulating the intracellular localization of NS1 
protein have been identified. While the critical impact of nuclear localization signal 
1 is well known, the other two localization signals have remained poorly 
characterized.  
 
In this work we provide a detailed description of the NS1 nuclear export signal 
(NES), showing that the NES region is well conserved within different influenza A 
strains and that certain mutations within the region cause attenuation of virus 
replication. Through the use of different mutant viruses, we show that the attenuated 
phenotype is not due to impaired localization alone, but rather involves defects in 
the functions of NS1. We also show that NS1 is not exported through the classical 
CRM1-dependent pathway and we establish the nucleolar proteins that bind NS1 
and thus guide its nucleolar localization. 
 
Human coronaviruses are a major cause of the common cold. For a long time 
coronaviruses were thought to cause only mild upper respiratory tract infections in 
humans. However, this view changed with the emergence of the highly lethal SARS 
coronavirus in 2002 and the identification of MERS coronavirus in 2012. While the 
SARS outbreak was efficiently contained, MERS coronavirus continues to circulate 
in camels and causes repeated introductions into the human population in the Middle 
East. Our MERS coronavirus research concentrated on characterizing MERS 
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infection of human macrophages and dendritic cells, two important cell types of the 
innate immune system. We show that MERS coronavirus does not replicate 
productively in these leucocytes, but a significant innate immune response is 
generated. 
 
Altogether this work identifies important aspects of virus-host interaction of two 
important respiratory pathogens. We provide new information on the mechanisms 
and impact of influenza A virus NS1 intracellular localization and we characterize 
MERS coronavirus infection in primary human leucocytes as well as highlight 
important differences in the host cell responses between MERS and SARS 
coronaviruses. 
 
Keywords: Influenza A virus, NS1, intracellular localization, MERS coronavirus, 
macrophage, dendritic cell 
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Tiivistelmä 
Hengitystievirusten aiheuttamat infektiot ovat maailmanlaajuisesti merkittävä 
sairastavuutta ja kuolleisuutta aiheuttava haaste kansanterveydelle. 
Vuosikymmenten tutkimustyö on tuottanut lukuisia läpimurtoja 
hengitystievirusinfektioiden mekanismien tuntemuksessa, mutta monet virusten 
taudinaiheutuskyvyn piirteet ovat yhä epäselviä. Rokotusten ja antiviraaliyhdisteiden 
kehitykseen suunnatut ponnistelut ovat tuottaneet lukuisia rokotteita ja lääkkeitä 
hengitystieviruksia vastaan, mutta ne ovat usein suojausteholtaan puutteellisia tai 
puuttuvat kokonaan tiettyjä virusryhmiä vastaan. Erilaisista eläinperäisistä lähteistä 
ilmaantuvat uudenlaiset virukset muodostavat erityisen uhkan, johon varautuminen 
edellyttää valmistautumista sekä valmiutta nopeisiin vastatoimiin. Viruksen ja 
isäntäsolun välisten vuorovaikutusten ymmärtäminen on keskeisessä asemassa 
kehitettäessä uusia parempia hoitomenetelmiä sekä valmistauduttaessa uusiin 
virusuhkiin. 
 
Viruksen ja isäntäsolun vuorovaikutuksiin keskittyvä tutkimuksemme käsittelee 
kahta merkittävää hengitystievirusta, influenssa A -virusta sekä MERS-
koronavirusta. Jo antiikin ajoista lähtien ihmiskunnan vitsauksena ollut influenssa A 
-virus aiheuttaa vuosittaisia talviaikaan sijoittuvia epidemioita sekä ajoittaisia 
maailmanlaajuisia pandemioita. NS1-proteiini on merkittävä influenssa A -viruksen 
virulenssitekijä, jolla on lukuisia infektiota edistäviä tai isäntäsolun immuunivastetta 
estäviä vuorovaikutuksia isäntäsolun proteiinien kanssa. Nämä vuorovaikutukset 
sijoittuvat sekä tumaan että solulimaan. NS1-proteiinista on tunnistettu kolme 
solunsisäistä paikantumista ohjaavaa signaalia, joista yhden tiedetään olevan tärkeä 
virusinfektiolle, mutta kahden muun merkitys on jäänyt epäselväksi. 
 
Tässä työssä luomme seikkaperäisen kuvauksen NS1-proteiinin tumasta solulimaan 
kulkeutumisen välittävän signaalin toiminnasta. Näytämme että kyseinen 
paikantumissignaali on hyvin säilynyt eri viruskantojen välillä ja osoitamme, että 
tietyt signaaliin kohdistuvat mutaatiot aiheuttavat viruksen replikaatiokyvyn 
huomattavan heikentymisen. Osoitamme erilaisten mutanttivirusten avulla, että 
heikentynyt fenotyyppi ei johdu ainoastaan NS1-proteiinin virheellisestä 
paikantumisesta, vaan aiheutuu NS1-proteiinin toiminnallisista vioista. Osoitamme 
myös, että NS1-proteiinin kulkeutuminen tumasta solulimaan ei ole CRM1-
välitteinen, sekä tunnistamme NS1-proteiinin kanssa vuorovaikuttavat 
tumajyväsproteiinit. 
 
Koronavirukset tunnetaan merkittävinä flunssan aiheuttajina ja niitä pidettiin pitkään 
lähinnä lievien hengitystieinfektioiden aiheuttajina ihmisissä, mutta tämä näkemys 
on muuttunut merkittävää kuolleisuutta aiheuttaneiden SARS- ja MERS-
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epidemioiden myötä. SARS-koronavirus ilmaantui vuonna 2002 ja saatiin nopeasti 
taltutettua, mutta vuonna 2012 havaittu MERS-koronavirus kiertää yhä kameleissa 
aiheuttaen toistuvia ihmisinfektioita Lähi-Idässä. MERS-koronavirusta käsittelevä 
osa työstämme keskittyi analysoimaan MERS-koronaviruksen vuorovaikutusta 
ihmisen makrofagien ja dendriittisolujen kanssa. Osoitamme, että MERS-
koronavirusinfektio ei johda merkittävään virusreplikaatioon näissä soluissa, mutta 
huomattava immuunivaste syntyy siitä huolimatta. 
 
Kaiken kaikkiaan työmme tuo ilmi tärkeitä piirteitä näiden merkittävien 
hengitystievirusten vuorovaikutussuhteista isäntäsolujen kanssa. Tuotamme uutta 
tietoa influenssa A -viruksen NS1-proteiinin solunsisäisen paikantumisen 
mekanismeista ja merkityksestä sekä analysoimme MERS-koronavirusinfektion 
piirteet ihmisen valkosoluissa korostaen samalla MERS- ja SARS-koronavirusten 
välisiä eroja. 
 
Avainsanat: Influenssa A -virus, NS1-proteiini, solunsisäinen paikantuminen, 
MERS-koronavirus, makrofagi, dendriittisolu 
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1 Review of the literature 
1.1 Lungs as an interface for host-pathogen interaction 
Because of its role as an organ of gas exchange, the lungs become regularly in direct 
interaction with the outside environment. Every day up to 9000 liters of air go 
through the lungs, providing a constant challenge of airborne particles, allergens and 
microbes (Kopf, Schneider & Nobs 2015). Appropriate responses to these different 
challenges are vital to the proper functioning of the lungs. Inappropriate responses 
against harmless agents can lead to severe complications like asthma, but at the 
same time invading pathogens must be stopped to maintain the integrity of the lungs. 
Various mechanisms of the innate and adaptive immune systems have evolved to 
protect the lungs against environmental challenges. 
A mechanical barrier consisting of the tightly junctioned lung epithelium and mucus 
secreted by goblet cells and other epithelial cells represents the simplest pulmonary 
defense against respiratory pathogens and harmful particles (Whitsett, Alenghat 
2015). Mucins comprising the gel-like mucus entangle microbes and prevent their 
adhesion to the epithelial cell surface (Voynow, Rubin 2009). The action of cilia on 
the epithelial cell surfaces moves the mucus towards the upper respiratory tract and 
thus works to remove particles and microbes from the lungs. The mucins themselves 
also have direct antimicrobial properties. Lung epithelial cells also secrete various 
kinds of antimicrobial peptides, defensins and surfactants and other host-defense 
proteins and influence the function of pulmonary macrophages and dendritic cells 
through cytokine production (Whitsett, Wert & Weaver 2010, Tecle, Tripathi & 
Hartshorn 2010).  
Macrophages and dendritic cells (DCs) are key constituents of the host immune 
system. Macrophages reside in tissues throughout the body and often act as first 
responders to microbial invasion (Gordon 2002). Besides their ability to 
phagocytose microbes and infected cells, macrophages also regulate inflammatory 
responses through production of inflammatory cytokines. DCs are antigen 
presenting cells and act as initiators and regulators of the adaptive immune response 
(Mellman, Steinman 2001). They form an important link between the innate and 
adaptive immune systems. In the lungs macrophages and dendritic cells are located 
near the epithelium and constantly sample the airway lumen for foreign material 
(Kopf, Schneider & Nobs 2015). Pulmonary macrophages and DCs form an 
interplay of interactions with each other and with the alveolar epithelial cells to 
regulate homeostasis and inflammatory responses against invading pathogens. 
Review of the literature 
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1.1.1 Lung-resident macrophages 
Lung-resident macrophages can be grouped into interstitial macrophages, bronchial 
macrophages and alveolar macrophages (Kopf, Schneider & Nobs 2015). Interstitial 
macrophages reside in the space between alveoli, where they interact with DCs and 
present antigens to interstitial T cells. Alveolar macrophages are located in the 
lumen of the alveoli attached to alveolar epithelial cells. A major function of 
alveolar macrophages is inhibiting inflammatory responses in the lung (Holt et al. 
1993). This is achieved by inhibition of T cell activation by DCs and secretion of 
TGF-β, which induces suppression of Th2 response by regulatory T cells 
(Josefowicz et al. 2012). Alveolar macrophages are also major producers of type I 
interferons (Kumagai et al. 2007). Close contact and interaction with alveolar 
epithelial cells is important in regulating the functions of alveolar macrophages 
(Westphalen et al. 2014). Integrins expressed on the surface of alveolar epithelial 
cells are essential for the activation of TGF-β secreted by alveolar macrophages 
(Munger et al. 1999). Alveolar epithelial cells also express CD200, which inhibits 
TLR activation in alveolar macrophages (Snelgrove et al. 2008). Activation of Toll-
like receptors in response to pathogen associated molecular patterns causes 
detachment of alveolar macrophages from the epithelium, resulting in waning of the 
suppressive properties of the macrophages and activation of inflammatory responses 
(Soroosh et al. 2013). The suppressive functions of alveolar macrophages are also 
important in restoring the normal state after clearance of infection, thus avoiding 
extensive immunopathological damage resulting from prolonged inflammation. 
Clearance of apoptotic cells is also an important function of alveolar macrophages 
during infection and has been shown to be critical in the host defence against 
influenza A virus infection (Hashimoto et al. 2007, Watanabe et al. 2005). 
1.1.2 Lung-resident dendritic cells 
The lung DC population consists of plasmacytoid dendritic cells (pDCs), monocyte-
derived dendritic cells (MDDCs) and conventional dendritic cells (cDCs), which can 
be further divided into CD11b+ DCs and CD103+ DCs based on integrin expression 
(Kopf, Schneider & Nobs 2015). Lung DCs are mainly localized just next to the 
epithelium on the basolateral side, where they sample the airway lumen with their 
tendril-like protrusions. MDDCs are known to stimulate Th1 responses in infected 
lung tissue and are potent inducers of pro-inflammatory cytokines (Iijima, Mattei & 
Iwasaki 2011). Plasmacytoid DCs have a role in preventing unnecessary responses 
to harmless inhaled antigens, can act as antigen presenting cells and are known as 
very strong producers of type I interferons in response to virus infection (de Heer et 
al. 2004, Colonna, Trinchieri & Liu 2004). Conventional DCs and especially 
CD103+ DCs are important in activating T cells through antigen presentation (del 
Rio et al. 2007). Upon phagocytosis, processing of antigen and maturation, DCs 
migrate into the draining lymph nodes and present antigens to CD8+ T cells 
Review of the literature 
 
 19  
 
(Mellman, Steinman 2001). CD103+ DCs favor induction of effector CD8+ T cells, 
whereas CD11b+ DCs seem to favor induction of memory CD8+ T cells because of 
differential CD24 expression (Kim et al. 2014). 
  
1.2 Respiratory viruses 
According to WHO, lower respiratory tract infections cause 3.1 million deaths each 
year, thus accounting for 5.5% of all annual deaths (WHO, Fact sheet N°310, 2014). 
Bacterial pathogens, especially Streptococcus pneumoniae, are the leading cause of 
community-acquired pneumonia, but a third of adult pneumonia cases are estimated 
to be caused by viruses (File 2003, Ruuskanen et al. 2011). Influenza viruses, 
respiratory syncytial virus, rhinoviruses, human metapneumovirus and 
coronaviruses are the most common viral causes of pneumonia and altogether they 
account for roughly 200 million viral pneumonia cases each year (Ruuskanen et al. 
2011). Influenza viruses are one of the most important respiratory pathogens due to 
annual epidemics resulting in up to 500 000 deaths and up to five million severe 
infections each year (WHO, Fact sheet N°211, 2014). In addition, influenza A virus 
causes occasional pandemics with potentially very high mortality (Elderfield, 
Barclay 2011). The most lethal pandemic to date was the Spanish flu pandemic of 
1918, causing up to 50 million casualties (Taubenberger, Morens 2006). Other 
influenza A pandemics of the last century include the Asian pandemic of 1957, the 
Hong Kong pandemic of 1968 and the recent swine flu pandemic of 2009 
(Elderfield, Barclay 2011). Vaccines and antiviral drugs are available against 
influenza viruses, but otherwise only supportive treatment is mostly available 
against viral pneumonia (Ruuskanen et al. 2011). 
 
Besides a hefty death toll, respiratory infections inflict a large economic burden on 
the society through lost working hours and increasing health care costs. One study 
estimated the annual cost of community-acquired pneumonia in the United States to 
be as high as 17 billion dollars (File, Marrie 2010). Adults are estimated to suffer 2-
4 common colds each year leading to millions of lost working days in the developed 
countries (Heikkinen, Jarvinen 2003). Rhinoviruses are the most common cause of 
the common cold with an estimated proportion of 30-50 % of all cases (Heikkinen, 
Jarvinen 2003). Coronaviruses and influenza viruses are also common causes with 
proportions of 10-15 % and 5-15 %, respectively. Other causative agents of the 
common cold include respiratory syncytial virus, metapneumovirus, parainfluenza 
viruses, adenoviruses and enteroviruses (Heikkinen, Jarvinen 2003). Rhinoviruses 
alone harbor a diversity of over 160 different serotypes and thus the sheer number of 
different causative agents makes the concept of a cure for the common cold an 
unrealistic notion. There are however various kinds of treatments available for the 
different symptoms associated with the common cold (Heikkinen, Jarvinen 2003). 
Review of the literature 
 
 20  
 
1.3 Influenza viruses 
Influenza viruses belong to the Orthomyxoviridae family and are divided into three 
genera of influenza A, influenza B and influenza C viruses (Fields Virology 2012). 
Influenza A viruses are further classified into subtypes according to the antigenic 
properties of the surface glycoproteins hemagglutinin and neuraminidase. Currently 
18 classes of hemagglutinin and 11 classes of neuraminidase are known (Tong et al. 
2012, Tong et al. 2013). Influenza B viruses are divided into Victoria-like and 
Yamagata-like lineages based on the phylogeny of hemagglutinin and 
neuraminidase genes. Influenza viruses are enveloped RNA viruses harboring a 
segmented single-stranded negative sense RNA genome of approximately 10-13 kb 
in size (Fields Virology 2012). They code for up to 16 proteins depending on the 
genus and specific strain (Chen et al. 2001, Wise et al. 2009, Jagger et al. 2012, 
Muramoto et al. 2013). Replication of influenza viruses takes place inside the host 
cell nucleus (Herz et al. 1981, Jackson et al. 1982). The segmented genome of 
influenza viruses enables genetic reassortment between different viral strains, 
allowing efficient exchange of large amounts of genetic information.  
 
Influenza C virus infects pigs and humans and causes mild upper respiratory tract 
infections (Guo et al. 1983). Influenza B virus has been isolated from seals in 
addition to humans and causes a similar disease as influenza A virus, characterized 
as an acute viral infection ranging from mild upper respiratory tract infections to 
severe viral pneumonia (Osterhaus et al. 2000). Influenza A virus infects birds, pigs, 
horses and other mammals in addition to humans (Yoon, Webby & Webster 2014). 
Wild aquatic birds are considered the natural reservoir of influenza A virus (Yoon, 
Webby & Webster 2014). In wild birds influenza A virus infects the respiratory and 
intestinal tracts and is typically asymptomatic, but outbreaks causing high mortality 
and economic losses in domestic poultry occur regularly (Franca, Brown 2014). 
Highly pathogenic avian strains are characterized by an insertion of basic amino 
acids in the hemagglutinin cleavage site, allowing cleavage by furin-like proteases 
and systemic spread of the infection in the host (Bottcher-Friebertshauser et al. 
2014). Avian influenza A strains bind to α2,3-linked sialic acid receptors as opposed 
to the α2,6-linked sialic acid receptors used by human strains (Rogers, Paulson 
1983). Human lungs contain α2,3-linked sialic acid receptors only in the lower 
respiratory tract, resulting in poor transmissibility of avian strains to humans but 
severe disease in the case of a successful transmission (Shinya et al. 2006). 
Pandemic influenza A strains arise from genetic reassortment between avian, human 
and/or swine strains, and pigs are thought to function as mixing vessels for 
pandemic strains, since they readily express both α2,3-linked and α2,6-linked sialic 
acid receptors in their airways (Elderfield, Barclay 2011). Currently two influenza A 
subtypes, H1N1 and H3N2, circulate in the human population causing annual 
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epidemics. Also avian subtypes H5N1 and H7N9 continue to circulate in poultry and 
cause outbreaks in humans. 
1.3.1 Pathogenesis of influenza A virus 
The clinical picture of influenza A varies from a mild upper respiratory tract 
infection to severe viral pneumonia. Common symptoms include sudden 
development of high fever, headache, cough, fatigue and malaise (Taubenberger, 
Morens 2008). Severe cases are associated with bronchitis, diffuse alveolar damage 
and pneumonia leading to acute respiratory distress syndrome (ARDS) 
(Taubenberger, Morens 2008). Death occurs due to respiratory and/or multiorgan 
failure. Fatal cases are often associated with secondary bacterial infection, especially 
Streptococcus pneumoniae -induced pneumonia (Madhi, Klugman & Vaccine 
Trialist Group 2004, Morens, Taubenberger & Fauci 2008). Young children and the 
elderly are particularly susceptible to severe influenza and many underlying medical 
conditions are also known to predispose to an adverse outcome (Thompson et al. 
2003, Thompson et al. 2004). Several different influenza A virus-specific antiviral 
drugs and biannually updated vaccines against seasonal influenza are available as 
treatment and prevention options (Tsiodras, Nikolopoulos & Bonovas 2012, Fiore, 
Bridges & Cox 2009).  
 
Influenza A virus can infect epithelial cells throughout the lungs, but severe 
infections are especially associated with infection of pneumocytes of the alveolar 
epithelium (Shinya et al. 2006, Taubenberger, Morens 2008). The more abundant 
type I pneumocytes express predominantly the α2,6-linked sialic acid receptors, 
whereas type II pneumocytes express the α2,3-linked sialic acid receptors (Shinya et 
al. 2006, van Riel et al. 2006, van Riel et al. 2007). Thus, the targeted cell type in 
the alveolus depends on the virus strain. Infection of the alveolar pneumocytes by 
influenza A virus damages the epithelium through virus-induced apoptosis or 
necrosis and causes production of proinflammatory cytokines, which results in early 
recruitment of neutrophils and monocytes to the alveolar lumen (Perrone et al. 2008, 
Short et al. 2014). Neuthrophils and monocyte-derived macrophages produce more 
proinflammatory cytokines further enhancing the inflammatory response and 
recruiting even more neutrophils and monocytes into the alveoli (Short et al. 2014). 
Neutrophils also produce reactive oxygen species and neutrophil extracellular traps, 
which damage and trap invading pathogens, but also have cytotoxic properties 
(Narasaraju et al. 2011, Amulic et al. 2012). Macrophages induce the formation of 
cytotoxic nitric oxide and peroxynitrite compounds through expression of nitric 
oxide synthase and induce apoptosis of alveolar epithelial cells by expressing 
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) (Fang 2004, 
Herold et al. 2008). Extensive tissue damage resulting from the actions of 
neutrophils and macrophages is a major contributor to the development of ARDS 
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during influenza A virus infection (Short et al. 2014). Magnitude of the host 
inflammatory response and neutrophil infiltration into the lungs have been found to 
be better indicators for the severity of disease than virus-induced tissue damage 
(Narasaraju et al. 2011, Brandes et al. 2013, Weiland et al. 1986). This excessive 
inflammatory response during influenza A infection has been termed ‘cytokine 
storm’ and is especially prominent in human infections with highly pathogenic avian 
strains (Cheung et al. 2002, Yuen, Wong 2005). Consistent with the 
immunopathologic features of influenza A virus infection, depletion of the 
immunosuppressive alveolar macrophages results in a fatal infection even with a 
low viral dose (Schneider et al. 2014). Infection of alveolar macrophages by 
influenza A virus has also been shown and might contribute to pathogenesis (van 
Riel et al. 2011). Despite the apparent detrimental effects imposed by the host innate 
immune responses, immunosuppressive compounds alone do not protect mice from 
lethal H5N1 infection and also depletion of neutrophils worsens rather than 
improves the disease outcome (Salomon, Hoffmann & Webster 2007, Tate et al. 
2011). 
 
Secondary bacterial infections are present in 30-90% of fatal influenza cases and 
bacterial pneumonia is a major cause of death of influenza patients (Mina, Klugman 
2014). Several influenza-induced effects have been identified that promote bacterial 
invasion (Mina, Klugman 2014). A major synergistic contributor seems to be 
excessive type I interferon production during co-infection (Shahangian et al. 2009). 
Type I interferons block Nod2-mediated recruitment of monocytes, reduce type 17 
T-helper cell polarization and inhibit CXCL1 and MIP-2 production (Nakamura, 
Davis & Weiser 2011, Kudva et al. 2011, Li, Moltedo & Moran 2012). Other 
synergistic aberrant immunomodulary effects include increased productions of IL-10, 
IL-12 and IFN-γ, which cause inhibition of neutrophil recruitment and reduce the 
expression of MARCO in alveolar macrophages (van der Sluijs et al. 2004, Sun, 
Metzger 2008). Influenza A infection also enhances bacterial carriage density and 
duration and has several other local and systemic effects that might contribute to 
secondary bacterial infection (Mina, Klugman 2014). 
 
Several influenza A viral factors have been identified as contributors towards severe 
disease. Most notable of these is the surface protein hemagglutinin (HA), which 
determines receptor specificity and is the major antigenic determinant and a decisive 
factor in the division of avian strains into highly pathogenic and low pathogenic 
strains based on the presence of a polybasic insertion near the HA cleavage site 
(Bottcher-Friebertshauser et al. 2014). The viral neuraminidase is indicated in 
enhancing bacterial adherence and replication through cleavage of sialic acids and 
exposure of bacterial receptors on the lung epithelium (McCullers, Bartmess 2003). 
Similarly, the influenza A virus protein PB1-F2 promotes viral pathogenesis and 
also contributes to secondary bacterial infection (McAuley et al. 2007). Other 
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established influenza A virus virulence factors include proteins of the polymerase 
complex and the non-structural protein 1 (NS1), which modulates a multitude of 
different host cell functions (Gabriel, Fodor 2014, Hale et al. 2008). 
 
1.3.2 NS1, a multifunctional antagonist of innate immune responses 
NS1 is considered one of the major virulence factors of influenza A due to its 
function as an antagonist of host innate immune responses (Hale et al. 2008, Garcia-
Sastre et al. 1998). NS1 prevents interferon production by the host cell by several 
mechanisms. Inhibition of mRNA processing and transport by NS1 through 
interaction with CPSF30 and PABII in the nucleus causes a general inhibition of all 
host cell protein expression (Nemeroff et al. 1998, Chen, Li & Krug 1999). NS1 
interaction with TRIM25 blocks the activation of the cytoplasmic RNA sensor RIG-
I (Gack et al. 2009). Other suggested targets for NS1 interaction within the RIG-I 
pathway include RIG-I itself and the ubiquitin E3 ligase Riplet, but these 
interactions might only represent co-binding to RNA as indicated by the requirement 
of a functional NS1 RNA-binding motif for these interactions (Pichlmair et al. 2006, 
Mibayashi et al. 2007, Rajsbaum et al. 2012). NS1 inhibits IKK-mediated NF-κB 
activation through interaction with IKK (Gao et al. 2012). NS1 also inhibits the 
action of IFN-induced antiviral proteins PKR and 2’-5’-oligoadenylate synthetase by 
direct interaction and sequestration of dsRNA, respectively (Min, Krug 2006, Min et 
al. 2007). 
 
Another recognized function of NS1 is activation of the PI3K pathway through 
binding to the p85β subunit of PI3K (Hale et al. 2006, Ehrhardt et al. 2006, Shin et 
al. 2007). PI3K is involved in many cellular processes, but activation of the 
downstream effector Akt and its suppressive function on apoptosis are thought to be 
the main target of NS1 PI3K activation (Ehrhardt et al. 2007). Direct binding of NS1 
to Akt has also been proposed (Matsuda et al. 2010). In addition, NS1 inhibits 
apoptosis by direct interaction and inhibition of the tumor suppressor p53 and by 
inhibition of Jun N-terminal kinase, which is involved in death receptor-mediated 
apoptosis signaling (Ludwig et al. 2002, Terrier et al. 2013, Wang et al. 2010). In 
some experimental settings NS1 has been found to promote apoptosis, but this has 
not been verified in the context of an infection (Lam et al. 2008). Besides the anti-
apoptotic functions of NS1, several influenza A proteins are known to induce host 
cell apoptosis (Chen et al. 2001, Wang et al. 2012). Thus, the control of apoptosis 
during influenza A infection appears to be a complex process probably leading to 
different outcomes with different virus strains and in different hosts. 
 
NS1 also has numerous other interactions with host cell proteins. NS1 promotes 
virus protein translation through interactions with viral mRNA, hStaufen and with 
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translation initiation factors eIF4GI and PABI (Park, Katze 1995, Falcon et al. 1999, 
Aragon et al. 2000, Burgui et al. 2003). NS1 affects splicing of viral mRNA through 
interaction with NS1-binding protein (Fortes, Beloso & Ortin 1994, Garaigorta, 
Ortin 2007, Tsai et al. 2013). NS1 interacts with and inhibits the host cell mRNA 
export machinery (Fortes, Beloso & Ortin 1994, Satterly et al. 2007). NS1 is also 
involved in temporal regulation of the viral infection (Min et al. 2007). NS1 targets 
and inhibits the human PAF1 transcription elongation complex through histone 
mimicry (Marazzi et al. 2012). The NS1 C-terminus of many avian strains forms a 
PDZ domain ligand, which allows interaction with many host proteins involved in 
various cellular processes, but the exact significance of these interactions for the 
virus infection is unclear (Obenauer et al. 2006, Jackson et al. 2008). NS1 
interaction with the cellular adapter proteins Crk and CrkL further enhance NS1-
mediated PI3K activation (Heikkinen et al. 2008, Ylosmaki et al. 2015).  
   
The many functions of NS1 are critical for influenza A virus infection. Studies with 
recombinant viruses lacking the NS1 gene have shown severe attenuation of the 
virus, but normal replication in IFN deficient systems (Garcia-Sastre et al. 1998). 
Similar studies using mutant viruses with specific NS1 interactions knocked out 
have indicated important roles for at least RNA binding, CPSF30 binding, PI3K 
binding and PAF1 binding (Min, Krug 2006, Noah, Twu & Krug 2003, Shin et al. 
2007, Marazzi et al. 2012). There is however a lot of strain and host dependent 
variation in the importance of any given NS1 function. 
 
1.3.3 Structure of NS1 
NS1 is a 26 kDa protein consisting of an N-terminal RNA-binding domain, a C-
terminal effector domain and a short linker region connecting the two domains (Hale 
et al. 2008). Both domains independently form homodimers through self-association 
and the full length NS1 also exists as a dimer both in vitro and in vivo (Nemeroff, 
Qian & Krug 1995, Liu et al. 1997, Bornholdt, Prasad 2006). Dimerization is 
essential for certain NS1 functions and lack of NS1 dimerization causes attenuation 
of the virus (Ayllon et al. 2012, Wang et al. 1999). NS1 has also been shown to form 
oligomers in structural studies and is speculated to form a tubular structure around 
dsRNA to prevent activation of cellular dsRNA sensors (Bornholdt, Prasad 2008). 
The length of NS1 varies from 202 to 237 amino acids and shows strain specificity 
with certain deletions or insertions often being associated with particular host ranges 
(Hale et al. 2008). Examples include a five amino acid deletion in the linker region 
of avian H5N1 strains, the seven amino acid C-terminal extension in human strains 
isolated between 1950 and 1989 and the 11 amino acid C-terminal deletion found on 
swine origin strains (Dundon, Capua 2009, Melen et al. 2007). The NS1 C-terminal 
region beyond amino acid 202 has been termed the “disordered tail” due to 
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difficulties in obtaining a structure for this region in crystallographic studies (Hale et 
al. 2008). This is speculated to be a consequence of intrinsic flexibility within the 
region and binding to a specific ligand might be needed to obtain an ordered 
conformation (Hale et al. 2008).  
 
Increasing evidence indicates that NS1 can adopt multiple different conformations to 
facilitate its many interactions (Hale 2014). This is made possible by the 
heterogeneity of the helix-helix interface of the effector domain dimer and by the 
flexibility of the linker region (Kerry et al. 2011, Aramini et al. 2014, Carrillo et al. 
2014). A model based on positioning of individual effector domains in relation to 
each other at the dimeric interface divides NS1 structures into ‘helix-closed’ and 
‘helix-open’ conformations depending on the availability of tryptophan 187 (Kerry 
et al. 2011). A similar division into ‘open’, ‘semi-open’ and ‘closed’ conformations 
can be made based on the length and flexibility of the linker region (Carrillo et al. 
2014). Additional conformations are formed upon NS1 binding to CPSF30 and PI3K 
(Das et al. 2008, Hale et al. 2010). An alternative strand-strand interface for the 
effector domain dimer observed in structural studies may offer still more 
conformational options (Bornholdt, Prasad 2006). Thus, current evidence depicts 
NS1 as a dynamic multiform protein that adopts a certain conformation based on the 
availability of ligands, NS1 concentration and possible specific regulatory 
mechanisms. No such regulatory mechanisms have been proven as of yet, but post 
translational modifications such as phosphorylation and SUMOylation are intriguing 
possibilities as structural regulators (Privalsky, Penhoet 1978, Xu et al. 2011). 
Evidence of NS1 conformation during infection obtained through the use of an 
antibody specific for ‘helix-open’ conformation showed only nuclear localization 
during the first 8 hours of infection, but ubiquitous localization throughout the cell at 
late stages of infection, suggesting that conformational prevalence of NS1 might be 
controlled temporally during infection (Kerry et al. 2011).  
 
Functional epitopes of NS1 are scattered throughout the protein and in many cases 
coincide with one another (Figure 1). Besides binding dsRNA, the RNA-binding 
domain contains a nuclear localization signal and interacts with TRIM25 (Gack et al. 
2009). The effector domain contains a nuclear export signal and interacts with 
TRIM25, PKR, CPSF30, PABII, p85β and many other host proteins (Hale et al. 
2008). There is a lot of NS1 sequence variation between strains and based on that 
variation NS1 proteins can be divided into alleles A and B, with most avian viruses 
grouping into allele B and human viruses into allele A (Treanor et al. 1989, Ludwig 
et al. 1991). Some of the regions of NS1 are more conserved than others and thus are 
thought to be structurally important (Darapaneni et al. 2009). 
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Figure 1. The structure of NS1. A) A cartoon depiction of the A/Udorn/72 NS1 RNA 
binding domain as a monomer. PDB ID 1AIL, source (Liu et al. 1997). B) A cartoon 
depiction of the A/Udorn/72 NS1 effector domain as a dimer. The C-terminal “tail” 
beyond amino acid 205 is not modeled in the structure due to its disordered nature. 
PDB ID 3EE8, source (Xia, Monzingo & Robertus 2009) C) A schematic 
representation of the A/Udorn/72 NS1 protein with the intracellular localization 
signals and some of the major interactions highlighted. Cartoon figures were 
generated using RasMol 2.7.5 software (www.rasmol.org). Colours in the cartoon 
structures depict NS1 interaction epitopes; NLS1/dsRNA binding – yellow, NES – 
red, TRIM25 – blue, CPSF30 – cyan. 
1.3.4 Intracellular localization of NS1 
Different functions of NS1 both in the nucleus and the cytoplasm necessitate a 
mechanism for nucleo-cytoplasmic transport. This is facilitated by the existence of a 
nuclear localization signal (NLS1), a nuclear export signal (NES) and a concurrent 
nuclear/nucleolar localization signal (NLS2/NoLS) in the NS1 structure (Melen et 
al. 2007, Greenspan, Palese & Krystal 1988, Li, Yamakita & Krug 1998). The NLS1 
is well conserved within different influenza A strains and comprises amino acids 
R35, R38 and K41 (Melen et al. 2007, Greenspan, Palese & Krystal 1988). The C-
terminal NLS2 is a classical bipartite NLS involving basic amino acids at positions  
219, 220, 224, 229, 231 and 232 (Melen et al. 2007). Unlike NLS1, NLS2/NoLS is 
only found in some strains and is not necessary for efficient nuclear import (Melen 
et al. 2007). The NS1 NES is a classical hydrophobic leucine-rich nuclear export 
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signal consisting of the amino acids F138, L141, L144 and L146 (Li, Yamakita & 
Krug 1998). During infection NS1 mostly localizes into the nucleus, but it is also 
found in the cytoplasm, especially at early and late stages of infection. Constant 
shuttling between the nucleus and cytoplasm is one possible mechanism for NS1 
localization, but the apparent temporal variation suggests an activating event for 
NS1 NES at a late stage of infection. Li and coworkers identified the NS1 amino 
acid region adjacent to NES as an inhibitory element and suggested binding to a 
viral protein to be necessary for NES activation, since NS1 in transfected cells 
remains entirely nuclear (Li, Yamakita & Krug 1998). Table 1 indicates the 
conservation rates of each NS1 localization signals within avian and human strains. 
While the NLS and NES signals are well conserved, the NLS2/NoLS is found fully 
functional in only a small percentage of strains. 
 
Table 1. Conservation rates of NS1 localization signals 
Amino 
acid 
Localiz. 
signal Avian   
Human 
H1N1   
Human 
H3N2   
position sequence Consensus Prevalence Consensus Prevalence Consensus Prevalence 
NLS Avian H1N1 H3N2 
34 x Asp 9997/10000 Asp 8103/8107 Asp 7078/7079 
35 Arg Arg 9995/10000 Arg 8104/8107 Arg 7077/7079 
36 x Leu 9937/10000 Leu 8084/8107 Leu 7011/7082 
37 x Arg 9985/10000 Arg 8099/8107 Arg 7072/7082 
38 Arg Arg 9997/10000 Arg 8104/8107 Arg 7083/7083 
39 x Asp 9996/10000 Asp 8101/8107 Asp 7079/7083 
40 x Gln 9995/10000 Gln 8105/8107 Gln 7081/7083 
41 Lys Lys 9886/10000 Lys 8096/8107 Arg 6721/7083 
42 x Ser 7900/10000 Ser 8104/8107 Ser 7002/7083 
NES Avian H1N1 H3N2 
137 x Ile 7509/10000 Ile 8120/8138 Ile 7012/7087 
138 Phe Phe 9599/10000 Phe 8127/8137 Phe 7075/7087 
139 x Asp 7497/10000 Asn 6367/8138 Asp 4451/7087 
140 x Arg 7820/10000 Arg 8133/8139 Arg 7072/7087 
141 Leu Leu 9816/10000 Leu 8137/8140 Leu 6994/7087 
142 x Glu 9869/10000 Glu 8130/8141 Glu 7071/7087 
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Consensus sequences for NS1 regions were calculated by analyzing up to 10000 
avian and human NS1 sequences from the Influenza Research Database –website 
(http://www.fludb.org) with the Analyze Sequence Variation (SNP) tool available 
on the website (Squires et al. 2012). 
 
 
 
 
 
143 x Thr 8163/10000 Thr 6772/8141 Thr 6726/7087 
144 Leu Leu 9997/10000 Leu 8133/8139 Ile 6179/7087 
145 x Ile 7593/10000 Ile 6634/8138 Val 6722/7087 
146 Leu Leu 7889/10000 Leu 8131/8138 Leu 7075/7087 
147 x Leu 9965/10000 Leu 8134/8138 Leu 7077/7087 
148 x Arg 9991/10000 Arg 8121/8138 Arg 7075/7087 
149 x Ala 9991/10000 Ala 8137/8139 Ala 7079/7087 
NoLS Avian H1N1 H3N2 
219 Lys Lys 7849/8100 Lys 8072/8093 Lys 6998/7031 
220 Arg Arg 7765/8071 Arg 1759/1768 Arg 6958/7000 
221 x Lys 5907/8057 Lys 1546/1768 Glu 4213/6989 
222 x Met 7642/8057 Met 1760/1768 Met 6982/6989 
223 x Ala 7800/8057 Ala 1763/1768 Ala 6963/6989 
224 Arg Arg 7839/8057 Gly 1616/1768 Arg 6826/6989 
225 x Thr 5717/7975 Thr 1713/1768 Thr 6974/6989 
226 x Ile 5809/7975 Ile 906/1768 Ala 6651/6989 
227 Arg Glu 7674/7975 Arg 1753/1768 Arg 6966/6989 
228 x Ser 7821/7975 Ser 1753/1768 Ser 6962/6986 
229 Lys Glu 7541/7938 Glu 1755/1767 Lys 4870/6985 
230 x Val 7711/7936 Val 1644/1767 Val 6937/6985 
231 Arg Arg 184/188 Arg 156/156 Arg 331/332 
232 Arg Gly 172/188 Arg 156/156 Arg 332/332 
233 x Asn 186/188 Asn 156/156 Asp 331/332 
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1.4 Coronaviruses 
Coronaviruses belong to the Nidovirales order and can be further divided into four 
genera of alpha-, beta-, gamma and deltacoronaviruses (Perlman, Netland 2009, 
Adams, Carstens 2012). Coronaviruses are enveloped RNA viruses harboring a 
single-stranded positive sense RNA genome of 27-32 kb in size (Woo et al. 2009). 
The large genome of coronaviruses is made possible by the action of a virus-
encoded exoribonuclease, which provides proofreading activity to the replication of 
the coronavirus genome (Denison et al. 2011). Two thirds of the coronavirus 
genome is composed of an open reading frame (ORF) coding for the replicase 
polyprotein 1a/1b and the rest contains ORFs coding for the structural proteins S, E, 
M and N, and a variable collection of accessory proteins (Figure 2) (Woo et al. 
2009). The 3’-proximal ORFs are expressed through the generation of a nested set of 
subgenomic RNAs to serve as templates for mRNA production (Fehr, Perlman 
2015). This is enabled by a mechanism where the coronavirus RNA-dependent RNA 
polymerase (RdRp) slows down at specific transcriptional regulatory sequences in 
the genome and either continues elongation or switches templates to the 5′end of 
the genome. The template switching property of the coronavirus RdRp makes 
coronaviruses prone for recombination, resulting in large variations in accessory 
gene composition between different coronaviruses and thought to make 
coronaviruses particularly adept at adapting to new host species (Graham, Baric 
2010). 
 
 
 
Figure 2. Genome organization of human coronaviruses. All coronaviruses encode 
for the replicase ORF 1a/1b and structural proteins spike (S), envelope (E), 
membrane (M) and nucleoprotein (N) (marked in gray). In addition, each strain 
encodes for several accessory proteins (yellow). Gene sizes are not drawn to precise 
scale. Adapted from (Liu et al. 2014). 
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Coronaviruses are the causative agents of gastrointestinal and respiratory tract 
infections in cows, pigs, chickens, dogs, cats and many other animal species (Fehr, 
Perlman 2015, Saif 2004). Coronaviruses impose a significant burden on the 
livestock industry with viruses like bovine CoV, infectious bronchitis virus and 
porcine hemagglutinating encephalomyelitis virus causing significant mortality in 
cattle, poultry and pigs. Bats are known to harbor most of the coronavirus diversity 
and they are suspected to be the origin of many human coronaviruses (Hu et al. 
2015). Six different human coronaviruses are currently known, including HCoV-
229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1 and MERS-CoV 
(Hamre, Procknow 1966, McIntosh, Becker & Chanock 1967, Peiris et al. 2003b, 
van der Hoek et al. 2004, Woo et al. 2005, Zaki et al. 2012). In humans 
coronaviruses mostly cause only mild upper respiratory tract infections and are 
estimated to account for 10-15% of all cases of common cold (Heikkinen, Jarvinen 
2003). Notable exceptions are SARS-CoV and MERS-CoV, which both cause 
severe respiratory tract infections with high mortality (Peiris et al. 2003a, Assiri et 
al. 2013). 
 
1.4.1 SARS-coronavirus 
SARS-CoV emerged in 2002, causing a worldwide epidemic with over 8000 
infected and almost 800 fatalities in 26 countries (WHO 2004). The first recorded 
incident of SARS-CoV infection was in November 2002, when a man from Foshan, 
China, was hospitalized due to atypical pneumonia (Zhong et al. 2003). SARS-CoV 
emerged as a global epidemic in March 2003, after a SARS-CoV infected man 
residing in a hotel in Hong Kong transmitted the disease to 16 other residents of the 
hotel and these individuals then spread the virus to Vietnam, Singapore and Canada 
(Centers for Disease Control and Prevention (CDC) 2003). Global public health 
efforts concentrated on rapid identification and isolation of new cases and proper 
infection control methods at hospitals successfully ended the outbreak by July 2003 
(Riley et al. 2003, WHO 2003a). The source of the virus was tracked to Chinese 
animal markets and specifically to Himalayan palm civets and raccoon dogs (Guan 
et al. 2003). A SARS-like coronavirus re-emerged in December 2003 causing four 
more human cases (Liang et al. 2004), which prompted mass cullings of civets and 
other animals in Chinese animal markets in January 2004 (Normile 2004). The virus 
has not been detected in palm civets or raccoon dogs after the cullings and no more 
human SARS-CoV cases have been recorded since 2004 (Kan et al. 2005). Bats are 
considered to be the natural reservoir of SARS-like coronaviruses based on 
isolations of very closely related viruses from Chinese horseshoe bats (Li et al. 
2005, Ge et al. 2013). 
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SARS-CoV is classified as a lineage b betacoronavirus and harbors a genome of 
almost 30 kb in size (Rota et al. 2003, Marra et al. 2003, Snijder et al. 2003). The 
genome organization of SARS-CoV resembles that of other coronaviruses, 
containing open reading frames for the 1a/1b polyprotein, the structural S, E, M and 
N proteins as well as eight accessory proteins. The eight accessory proteins of 
SARS-CoV are involved in a multitude of different host cell functions, including 
apoptosis, cell cycle regulation, DNA synthesis and activation of the innate immune 
response (Liu et al. 2014). None of the accessory proteins are absolutely required for 
SARS-CoV replication, but the IFN antagonist Orf6 is a known virulence factor 
(Pewe et al. 2005, Kopecky-Bromberg et al. 2007). 
 
1.4.2 Pathogenesis of SARS-CoV 
SARS-CoV is the causative agent of a condition termed severe acute respiratory 
syndrome (SARS), which manifests itself as viral pneumonia featuring a rapid 
development of abnormalities in chest radiography (Peiris et al. 2003a). Typical 
clinical symptoms include fever, dry cough, myalgia, malaise and chills (Peiris et al. 
2003a, Peiris, Guan & Yuen 2004, Hui, Memish & Zumla 2014). There is a high 
prevalence of lymphopenia and some patients develop watery diarrhea during the 
illness (Peiris et al. 2003a). Severe cases develop into acute respiratory distress 
syndrome (ARDS) often requiring mechanical ventilation. The main cause of death 
is respiratory failure due to extensive alveolar damage (Nicholls et al. 2003). The 
mean incubation time is 4.6 days with a range of 2 to 14 days (Hui, Memish & 
Zumla 2014). Viral load remains relatively low for the first few days of infection 
and peaks at 10 days after the onset of symptoms (Peiris et al. 2003a). Due to the 
lack of coronavirus specific drugs, treatment of SARS was mostly restricted to 
supportive treatment. Some patients were treated with the purine nucleoside 
analogue ribavirin, but no clinical benefits were found in a retrospective study 
(Leong et al. 2004). Treatment with lopinavir and ritonavir appeared to have some 
benefit as an initial treatment (Chan et al. 2003). Corticosteroids were used widely 
in Asia as a treatment for SARS and reportedly contributed to lower mortality in 
some cases, but they also caused long term complications in treated patients (Chen 
et al. 2006, Lv et al. 2009). In the end, not enough clinical evidence accumulated 
during the epidemic to suggest beneficial effects for any of the aforementioned 
treatments (Stockman, Bellamy & Garner 2006). 
 
The receptor for SARS-CoV is the metallopeptidase ACE2, which is expressed in 
various human tissues (Li et al. 2003, Hamming et al. 2004). The SARS-CoV S 
protein needs activation by host cell proteases to facilitate virion-cell fusion and thus 
protease expression by the target cell is also a factor in SARS-CoV tissue tropism 
(Millet, Whittaker 2015). The transmembrane protease TMPRSS2 is considered the 
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principal protease involved in SARS-CoV S protein activation, although there is also 
evidence suggesting the involvement of cathepsin L and HAT (Simmons et al. 2005, 
Matsuyama et al. 2010, Bertram et al. 2011). Both ACE2 and TMPRSS2 are widely 
expressed in human lung tissue, including type II pneumocytes (Hamming et al. 
2004, Bertram et al. 2012).  
 
Type II pneumocytes of the alveolar epithelium are considered the primary target of 
SARS-CoV infection in the lungs based on data from immunohistochemical analysis 
of patient samples and in vitro infection experiments (Tse et al. 2004, Nicholls et al. 
2006, Mossel et al. 2008). SARS-CoV infection of type II pneumocytes in vitro 
results in a robust innate immune response and similar strong cytokine responses 
have also been detected in patient samples (Jiang et al. 2005, Qian et al. 2013). 
Efficient migration of macrophages to the alveoli has been detected in post mortem 
tissue samples of patients and there is some evidence of infection of alveolar 
macrophages by SARS-CoV in patient samples, but monocyte-derived macrophages 
and dendritic cells do not support productive replication of SARS-CoV in vitro 
(Nicholls et al. 2003, Nicholls et al. 2006, Ziegler et al. 2005). Reported 
extrapulmonary targets for SARS-CoV include tissues of the gastrointestinal system, 
kidney, skin, liver, spleen, lymph nodes, pancreas and brain, but diarrhea and 
lymphopenia are the only consistently observed major pathological features outside 
the lungs (Peiris et al. 2003a, Ding et al. 2004, Gu et al. 2005, Li et al. 2003). 
Extensive T cell lymphopenia is strongly associated with the acute phase of SARS-
CoV infection in patients (Li et al. 2004). Infection of T cells by SARS-CoV has 
been suggested as the mechanism for the lymphopenia, but evidence supporting this 
conclusion is controversial (Gu et al. 2005, Chan, Chen 2008). Instead, lymphopenia 
during SARS-CoV infection might be a consequence of stress-mediated induction of 
blood cortisol levels further amplified by glucocorticoid treatment, which is known 
to cause lymphopenia (Panesar et al. 2004). Since many SARS patients were treated 
with glucocorticoids, it is difficult to estimate how much of the lymphopenia 
observed in SARS patients is due to glucocorticoid treatment and how much due to 
direct or indirect influence by SARS-CoV (Sung et al. 2004). Inefficient activation 
of dendritic cells in the lungs and subsequent weak migration to lymph nodes and 
lack of a T cell response have been shown to result in a severe disease in SARS-
CoV infected mice and a similar mechanism has also been suggested for humans 
(Zhao et al. 2009). This hypothesis is supported by the findings of Yoshikawa and 
coworkers, who suggested that cytokine production of lung epithelial cells in 
response to SARS-CoV infection causes inhibition of T cell priming ability of 
monocyte-derived dendritic cells (Yoshikawa et al. 2009).   
 
A defining feature of the SARS epidemic was the notable association of severe 
disease with old age. In Hong Kong, where there were 1755 cases and 298 deaths 
during the 2002-2003 epidemic, no casualties under the age of 25 were recorded, 
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whereas death rates of over 50% were observed in patients over 65 years old (Peiris, 
Guan & Yuen 2004, WHO 2003b). The same phenomenon is also seen in 
experimental animals, where mice and macaques show similar age-associated 
increase of disease severity (Roberts et al. 2005, Smits et al. 2010). Age-related loss 
of naive T cells and changes in their function and repertoire are well known factors 
in respiratory infections of the elderly, but an additional mechanism affecting 
dendritic cell migration during SARS-CoV infection has been suggested (Zhao et al. 
2011, Goronzy et al. 2015). Studies in mice have attributed age-related association 
of severe SARS to increased expression of prostaglandin PGD2 in the lungs of old 
mice, which results in impaired migration of dendritic cells from the lungs to the 
lymph nodes and a weakened T cell response (Zhao et al. 2011). Such a mechanism 
could be a factor in SARS-CoV pathogenesis in humans as well. 
 
These observations suggest a model of SARS-CoV pathogenesis involving infection 
of type II pneumocytes of the alveolar epithelium and replication to high titers in the 
lung (Tse et al. 2004, Nicholls et al. 2006). SARS-CoV induces early production of 
IL-6, IL-8, CXCL10 and other cytokines, but inhibits IFN production (Tang et al. 
2005, Yoshikawa et al. 2009). Lung resident macrophages and dendritic cells are not 
productively infected by SARS-CoV, but further contribute to inflammation by 
producing inflammatory cytokines and chemokines (Ziegler et al. 2005, Law et al. 
2005, Yoshikawa et al. 2009). Dendritic cells are poorly activated, resulting in weak 
migration to the lymph nodes and a weak T cell response (Yoshikawa et al. 2009). 
This is especially emphasized in elderly patients with their already weakened T cell 
response and enhanced PGD2 expression in the lung (Zhao et al. 2011, Goronzy et 
al. 2015). Lymphopenia, whether drug- or virus-induced, further diminishes the T 
cell response (Panesar et al. 2004). A weak T cell response leads to delayed virus 
clearance from the lungs and continued replication and inflammation. ARDS 
develops due to diffuse alveolar damage induced by viral replication in the alveolar 
epithelium and neutrophil and T cell mediated destruction of alveolar epithelial cells 
(Perlman, Netland 2009, Nicholls et al. 2003). 
 
1.4.3 MERS-coronavirus 
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first 
identified in Saudi-Arabia in 2012 from a man suffering from atypical pneumonia 
(Zaki et al. 2012). Since then over 1600 infections and over 500 deaths have been 
reported (WHO, 2016). The ongoing MERS-CoV epidemic is mostly concentrated 
in the Middle East and Saudi-Arabia, but cases have been exported by travelers to 
over 25 countries causing occasional secondary spread. Most notable outbreak 
outside Saudi Arabia took place in South Korea in 2015, resulting in 186 reported 
cases (Korea Centers for Disease Control and Prevention 2015). Dromedary camels 
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are the zoonotic source of human infections and MERS-CoV has reportedly been 
circulating in camels for decades (Azhar et al. 2014, Corman et al. 2014b, Reusken 
et al. 2013, Raj et al. 2014). The exact transmission route from dromedary camels to 
humans is still unclear, and besides direct contact might include consumption of raw 
camel milk and meat (Reusken et al. 2014, Hemida et al. 2015). Evidence for a bat 
reservoir of MERS-CoV has also been detected, suggesting a possible bat origin of 
MERS-CoV (Memish et al. 2013, Corman et al. 2014a, Ithete et al. 2013, Wang et 
al. 2014). Human to human transmission of MERS-CoV is not efficient and the R0 
has been estimated to be 0.7 (Chowell et al. 2014). The epidemic persists due to 
repeated introductions to the human population from dromedary camels. 
 
MERS-CoV is taxonomically a betacoronavirus like SARS-CoV, but is classified in 
a different lineage (Zaki et al. 2012). The closest known relatives to MERS-CoV are 
bat coronaviruses BatCoV-HKU4 and BatCoV-HKU5. The MERS-CoV genome is 
30 kb in size and contains ORFs coding for five accessory proteins in addition to the 
typical coronavirus ORFs for the 1a/1b polyprotein and the structural proteins (van 
Boheemen et al. 2012). Accessory proteins ORF4a, ORF4b and ORF5 have known 
roles in blocking the host innate immune response, but the functions of ORF3 and 
ORF8b remain presently unknown (Yang et al. 2013, Niemeyer et al. 2013). No 
sequence similarity is shared between the accessory proteins of MERS-CoV and 
SARS-CoV. Studies concerning the evolution of MERS-CoV indicate no significant 
changes in the MERS-CoV genome during this epidemic (Cotten et al. 2014). 
 
1.4.4 Pathogenesis of MERS-CoV 
The clinical picture of MERS has many similarities with SARS (Hui, Memish & 
Zumla 2014). Most patients present with mild to severe respiratory disease 
accompanied with fever, chills, cough, shortness of breath and abnormal chest 
radiography (Assiri et al. 2013). Other common symptoms include myalgia, malaise, 
diarrhea and lymphopenia (Assiri et al. 2013). A strikingly large proportion of 
patients have been reported to suffer from some kind of underlying medical 
condition, most commonly diabetes or renal disease. The disease is typically milder 
and even asymptomatic in patients without comorbidities (WHO Mers-Cov 
Research Group 2013). Severe disease is associated with rapid progression into 
pneumonia requiring mechanical ventilation. Renal failure and thrombocytopenia 
are common extrapulmonary complications in severe cases (Arabi et al. 2014). 
Death results from ARDS, septic shock or multi-organ failure (Who Mers-Cov 
Research Group 2013). The overall mortality rate is over 30%, but this figure might 
be inflated due to asymptomatic cases going undetected. The mean incubation time 
is 5.2 days with a range of 2 to 13 days (Assiri et al. 2013). Like with SARS, the 
treatment of MERS patients is largely concentrated on supportive treatment. Some 
Review of the literature 
 
 35  
 
patients have been treated with corticosteroids, but with little benefit. Ribavirin and 
interferon-α2b have been reported to be effective in treatment of MERS-CoV-
infected rhesus macaques, but so far convincing clinical evidence supporting their 
use is missing (Falzarano et al. 2013). 
 
The receptor for MERS-CoV is dipeptidyl peptidase 4 (DPP4) (Raj et al. 2013). 
DPP4 is expressed in many parts of the lung and especially in the alveolar regions, 
and can also be found in many other human tissues (Meyerholz, Lambertz & 
McCray 2016, Lambeir et al. 2003). MERS-CoV S protein can be cleaved by 
TMPRSS2, which is expressed throughout the lung (Bertram et al. 2012, Gierer et 
al. 2013). In addition, several other host cell proteases have been shown to cleave 
MERS-CoV S protein (Shirato, Kawase & Matsuyama 2013, Burkard et al. 2014, 
Millet, Whittaker 2014, Zmora et al. 2014).  
 
A recently published autopsy study of a lethal case of MERS identified type II 
pneumocytes and epithelial syncytial cells as the main targets for MERS-CoV 
infection (Ng et al. 2016). Infection of bronchial submucosal glands was also 
observed and suggested to contribute to MERS-CoV transmission as a means to 
access respiratory secretions. The major pathological feature observed in the lungs 
was diffuse alveolar damage, suggesting a similar mechanism to SARS-CoV of 
ARDS formation due to viral replication in the alveolar epithelium. No infiltration 
of neutrophils or macrophages were reported, indicating that excessive inflammation 
might not be a feature of MERS-CoV pathogenesis. Pulmonary macrophages were 
not infected by MERS-CoV. Despite previous observations of MERS-CoV RNA in 
the blood and urine of patients and prevalence of renal failure in fatal cases 
suggesting systemic infection, no evidence of extrapulmonary infection was found 
in the brains, kidney, liver, spleen, lymph nodes, bone marrow, small intestine or 
colon (Ng et al. 2016, Poissy et al. 2014, Drosten et al. 2013). The exact cause of 
death was not mentioned, but the patient developed hypotension and renal failure 
and required mechanical ventilation before death. 
 
The median age of MERS-CoV patients is 50 years, making old age a significant 
risk factor for MERS-CoV infection (WHO, 2015). This might reflect a similar 
scenario hypothesized for SARS-CoV, where the host T cell response has a critical 
role in viral pathogenesis. MERS-CoV is able to infect T cells in vitro, but the 
autopsy study by Ng and coworkers reported no infection of lymph nodes or spleen 
(Ng et al. 2016, Chu et al. 2016). Conflicting results have been published on 
dendritic cell permissibility for MERS-CoV infection (Chu et al. 2014, Scheuplein 
et al. 2015). 
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A clear model of MERS-CoV pathogenesis cannot be currently formed. The autopsy 
report by Ng and coworkers is in many aspects contradictory to previous data from 
animal models of MERS-CoV infection. Infection of common marmosets causes 
moderate to severe disease characterized by infection of type I pneumocytes and 
alveolar macrophages, strong inflammation of the lung and widespread systemic 
infection (Falzarano et al. 2014, Baseler et al. 2016). Similar results are seen in ex 
vivo infection of human lung tissue (Hocke et al. 2013). Analysis of a 
bronchoalveolar lavage sample from a MERS patient showed infection of lung 
epithelial cells and apoptosis (Hocke et al. 2013). While the autopsy data presented 
by Ng and coworkers is the most convincing evidence on MERS-CoV pathogenesis 
so far, it is still based on only one autopsy. Large individual variations are seen in 
the clinical manifestations and in activation of innate immune responses between 
patients (Faure et al. 2014). Therefore, more evidence is needed to clarify the 
pathogenesis of MERS-CoV. 
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2 Aims of the study 
The specific aims of this study were: 
 
 1. To determine the critical amino acids for influenza A NS1 nuclear 
 export signal (NES) function during infection 
 
 2. To study the importance of NS1 NES for influenza A pathogenesis 
 
 3. To investigate the mechanics of NS1 interaction with the host cell 
 nuclear export machinery and the nucleolus 
  
 4. To determine susceptibility of primary human leukocytes to 
 MERS-CoV infection and to compare innate immune responses 
 caused by MERS-CoV to those induced by SARS-CoV 
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3 Materials and Methods 
3.1 Cells 
Differentiation of macrophages and DCs from monocytes derived from voluntary 
blood donors was done as previously described (Osterlund et al. 2005, Pirhonen et 
al. 1999). Macrophages and DCs were identified by their typical morphology. 
Macrophage–serum-free substitution medium supplemented with 0.6 µg/ml 
penicillin, 60 µg/ml streptomycin and 10 ng/ml human granulocyte–macrophage 
colony-stimulating factor (GM-CSF) and RPMI medium supplemented with 0.6 
µg/ml penicillin, 60 µg/ml streptomycin, 2 mM L-glutamine, 20 mM HEPES, 10% 
fetal calf serum (FCS), 10 ng/ml GM-CSF and 20 ng/ml IL-4 were used in the 
maintainance of macrophages and MDDCs, respectively. Macrophages were used at 
7 days and MDDCs at 6 days after cultivation. 
 
Cell lines used in this study were maintained in Eagle minimum essential medium 
supplemented with 0.6 µg/ml penicillin, 60 µg/ml streptomycin, 2 mM L-glutamine, 
20 mM HEPES and 10% FCS at 37°C in 5% CO2. All the used cell lines are listed 
in Table 2. 
 
Table 2. Cell lines used in the study. 
Cell line Source Study 
A549 ATCC CCL-185 I, II, III 
Calu-3 ATCC HTB-55 III 
HEK293 ATCC CRL-1573 I 
HuH7 Nakabayashi et al. II 
MDCK ATCC CCL-34 I, II, III 
Vero ATCC CCL-81 III 
Vero E6 ATCC CRL-1586 III 
 
3.2 Viruses 
Mutant influenza A viruses were generated using the reverse genetics system 
described by Neumann and coworkers and passaged twice on MDCK cells 
(Neumann et al. 1999). Propagation of final stocks of influenza A viruses used in 
this study was done in 11-day old embryonated chicken eggs at +34 °C for 3 days. 
Stock titers were determined by plaque titration on MDCK cells. Correct sequences 
of mutant virus stocks were verified by sequencing. Coronaviruses were propagated 
for two passages on Vero E6 cells and stock titers were determined by end-point 
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dilution assay. Propagation of and all experiments with coronaviruses were done in 
biosafety level 3 conditions. All the viruses used in this study are listed in Table 3. 
 
Table 3. Viruses used in the study.  
Virus Subtype Titer (pfu/ml) Study 
A/Udorn/72 H3N2 2x107 I, II 
A/Udorn/72 NS1 (F138A, 
L141A) H3N2 1.5x108 I 
A/Udorn/72 NS1 (L141A) H3N2 1x107 I 
A/Udorn/72 NS1 (L144A, 
L146A) H3N2 4x106 I 
A/Udorn/72 NS1 (L146A) H3N2 2x107 I 
A/Udorn/72 NS1 (A149V) H3N2 1.6x107 I 
A/WSN/33 H1N1 2x107 II 
A/WSN/33 (A/Brevig 
Mission/1/18 segm 8) H1N1 1-4x107 II 
A/Fin/554/09 H1N1 1-4x107 II 
A/mallard/Netherlands/12/2000 H7N3 1-4x107 II 
A/Beijing/89 H3N2 6x107 III 
SARS-CoV 
HKU-
39849 
2.5x107 
TCID50/ml III 
MERS-CoV 
GenBank 
JX869059 
1.5x106 
TCID50/ml III 
 
3.3 Antibodies 
All the antibodies used in this study for either immunofluorescence or Western blot 
are listed in Table 4. 
 
Table 4. Antibodies used in the study. 
Antibody Source Study 
Guinea pig anti-NS1 Melen et al. 2007 I, II 
Rabbit anti-NP Ronni et al. 1995 I 
Rhodamine Red X-goat anti-
guinea pig Ig Jackson ImmunoResearch I 
FITC-anti-rabbit Ig Jackson ImmunoResearch I 
FITC- goat anti-guinea pig Ig Jackson ImmunoResearch II 
Rabbit anti-Actin 
sc-10731, Santa Cruz 
Biotechnology I, III 
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Rabbit anti-MxA Ronni et al. 1993 I, III 
Rabbit anti-p-IRF3 
#4947, Cell Signaling 
Technology I 
Rabbit anti-p-Akt 
#9271, Cell Signaling 
Technology I 
Rabbit anti-M1 housemade I 
Rabbit anti-NEP housemade I 
HRP-conjugated rabbit anti-
guinea pig Dako I, III 
HRP-conjugated goat anti-rabbit Dako I, II, III 
HRP-conjugated goat anti-mouse Dako II 
Mouse anti-nucleolin 
sc-8031, Santa Cruz 
Biotechnology II 
Mouse anti-B23 
sc-32256, Santa Cruz 
Biotechnology II 
Rabbit anti-fibrillarin #2639, Cell Signaling  II 
Rabbit anti-HIV-1 Rev Malim, Cullen 1991 II 
Guinea pig anti-SARS-CoV N Ziegler et al. 2005 III 
Rabbit anti-MERS-CoV N Adney et al. 2014 III 
Rabbit anti-MERS-CoV N Sino Biological III 
Rabbit anti-human DPP4 AbCam III 
 
3.4 qRT-PCR primers 
Primers used in the qRT-PCR assays of the study are listed in Table 5. 
 
Table 5. qRT-PCR primers used in the study 
Primer target Source Study 
SARS-CoV ORF1b Drosten et al. 2003 III 
MERS-CoV ORF1b Corman et al. 2012 III 
IFN-beta Hs00277188_s1, Life Technologies III 
IFN-lambda1 Hs00601677_g1, Life Technologies III 
CXCL10 Hs00171042_m1, Life Technologies III 
TNF-alfa Hs01113624_g1, Life Technologies III 
MxA Hs00182073_m1, Life Technologies III 
Human DPP4 10031225, BioRad III 
18S rRNA 4308329, Life Technologies III 
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3.5 Methods 
All the methods used in this study are listed in Table 6. Specific details for each 
method are provided in the materials and methods sections of the individual 
publications. 
 
Table 6. Methods used in the study 
Method Study 
Cell culture I, II, III 
Virus propagation in embryonated chicken eggs I, II, III 
Reverse genetics I, II 
Site-directed mutagenesis I, II 
Plasmid isolation I, II, III 
Transfection I, II 
Transformation I, II 
Plaque titration I, II 
Sequencing I, II 
Immunofluorescence I, II 
Protein expression in E. coli I, II 
GST-pulldown I, II 
SDS-PAGE I, II, III 
Western blot I, II, III 
Virus infection experiments I, II, III 
Endpoint dilution assay I, III 
ELISA I, III 
Confocal laser microscopy I, II 
In vitro translation I, II 
Isolation and differentiation of monocytes III 
RNA isolation III 
qRT-PCR III 
cDNA synthesis III 
Student’s t-test. I, III 
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4 Results and discussion 
4.1 Elucidating the significance of NS1 intracellular 
localization for influenza A virus infection 
Besides influenza A virus, several other viruses are known to encode proteins that 
are targeted into the nucleus as part of their function as antagonizers of host cell 
transcription and anti-viral response. Examples include respiratory syncytial virus 
matrix protein and dengue virus nonstructural protein 5 (Ghildyal et al. 2003, 
Brooks et al. 2002). Inhibition of either nuclear import or export through mutation or 
inhibitors has identified nucleo-cytoplasmic transport of these proteins to be critical 
for virulence and virus production (Ghildyal et al. 2009, Pryor et al. 2007, 
Rawlinson et al. 2009). Nuclear localization of influenza A virus NS1 protein is 
known to be critical for inhibition of IFN-β mRNA production, but studies on NS1 
nuclear export are largely missing (Min, Krug 2006, Donelan, Basler & Garcia-
Sastre 2003). In study I we focused on the NS1 NES with the aims of determining 
the critical amino acids needed for nuclear export of NS1 during infection and 
studying the impact of NS1 NES abolishment on influenza A virus infection. 
 
The NS1 NES was identified more than 15 years ago, but since then its functions 
have not been studied much further (Li, Yamakita & Krug 1998). The study by Li et 
al. used transfected fusion constructs of GST fused to NS1 fragments to identify the 
NES sequence as well as two critical amino acids (L144 and L146) and an adjacent 
inhibitory region. We wanted to extend these observations by taking a detailed look 
at NS1 NES function during infection. To that end we generated recombinant 
A/Udorn/72 viruses harboring different point mutations in the NS1 NES sequence. 
Analysis of NS1 localization in infected A549 cells 8-24h post infection by 
immunofluorescence revealed that the L146A mutation by itself was not sufficient 
to abolish NES function (I, Fig. 2 and 3). Localization of NS1 L146A was mostly 
similar to wild-type NS1 with NS1 L146A localizing both in the nucleus and the 
cytoplasm throughout infection. When combined with L144A, the resulting double 
mutation L144A, L146A inactivated the NES efficiently resulting in almost 
exclusively nuclear localization of NS1 at later stages of infection (I, Fig. 2 and 3). 
The other introduced mutations (L141A; F138A, L141A and A149V) were similarly 
effective in inactivating the NS1 NES, indicating that leucines 141 and 144 are both 
critical for NS1 NES function. Interestingly, our data did not support the finding of 
Li et al. on the critical nature of leucine 146 for NS1 NES function (Li, Yamakita & 
Krug 1998). An obvious explanation for this discrepancy could be the differences in 
experimental settings, as Li et al. based their observation on transfection 
experiments using only the NES region fragment of NS1 bound to GST. Our data is 
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more likely to reflect the actual mechanism since it was obtained using full length 
NS1 proteins in the context of an infection. Differences in virus strains and cell lines 
is also a possible reason for the different observations as many NS1 functions have 
been shown to be strain and host specific. Our observation that the point mutation 
A149V also inactivates the NS1 NES supports the description by Li et al. of the 
region adjacent to NES acting as a regulatory element. The alanine 149 is not part of 
the NS1 NES sequence as shown by Li et al., but our data fits well with the idea of a 
regulatory function for the region adjacent to NES since a mutation within this 
region could have either activating or inhibiting consequences for the NES function 
depending on the mutation. 
 
The NS1 NES region is highly conserved within all influenza A isolates (I, Table 1), 
suggesting structural or functional importance for the region. Thus, we expected 
several of the mutant viruses to display an attenuated phenotype in infection 
experiments. Growth kinetic experiments done in MDCK cells at MOI 0,001 
showed impaired growth properties for the mutant viruses (L144A, L146A) and 
(A149V), whereas all the other mutant viruses grew to similar titers as the wild-type 
virus (I, Fig. 4). Similarly, in A549 cells the same viruses stood out as the only ones 
to cause significant production of IFN-beta and IFN-lambda 1 (I, Fig. 6A and 6B). 
Further examination of the infections on protein level revealed some variation in the 
expression kinetics of viral proteins, but overall the differences remained minor (I, 
Fig. 5). Some increase in MxA production and phosphorylation of IRF3 as 
compared to the wild-type virus was seen with all the mutant viruses with the most 
pronounced increases being associated with mutations (L144A, L146A) and 
(A149V) (I, Fig. 6C). Interestingly, a decrease in phosphorylation of Akt was seen 
with the mutant viruses (L144A, L146A) and (A149V), indicating an impairment of 
PI3K activation by NS1 (I, Fig. 6C). Overall, introduction of point mutations into 
the conserved NS1 NES region caused several changes in phenotype, but the 
changes correlated poorly with NS1 localization. Most clear changes were seen with 
the mutant viruses (L144A, L146A) and (A149V), which both also displayed a 
mostly nuclear NS1, but the changes in phenotype have to be attributed to other 
factors besides intracellular localization of NS1 because the mutations (F138A, 
L141A) and (L141A) also caused nuclear retention of NS1 without affecting viral 
growth properties or IFN antagonism. 
 
Besides the NES, several other functional roles have been assigned to the 138-150 
amino acid region of NS1. NS1-mediated inhibition of CPSF by binding to its 30 
kDa subunit (CPSF30) is considered one of the main mechanisms for inhibiting host 
cell protein production during influenza A virus infection. The NS1 NES region has 
been suggested to be involved in CPSF30 binding with the amino acid 144 playing a 
critical role in the binding (Twu et al. 2006). Impairment of CPSF inhibition by NS1 
could very well explain many phenotypic features of our NES mutant viruses, as the 
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loss of NS1 CPSF binding function has been shown to cause attenuation of influenza 
A virus (Noah, Twu & Krug 2003). However, a crystal structure published on the 
NS1-CPSF complex does not support the idea of the NES region being involved in 
the binding (Das et al. 2008). To analyze whether our NES mutations affected CPSF 
binding, we introduced the same mutations into GST-NS1 expression plasmids. A 
pull-down assay using [35S]-labeled CPSF30 showed similar binding with the 
mutant NS1 proteins and the wild-type NS1, indicating that CPSF binding was not 
impaired (I, Fig. 7). Inhibition of mRNA export is another feature attributed to the 
NS1 NES region (Qian, Alonso-Caplen & Krug 1994). Qian et al. reported the loss 
of mRNA export inhibition by NS1 when either leucine 144 or leucine 146 was 
mutated into an alanine. Also mutation of NS1 amino acids 143, 145 and 147 
abolished mRNA export inhibition, but mutation L141A had no effect (Qian, 
Alonso-Caplen & Krug 1994). A later study showed that NS1 binds four different 
proteins of the mRNA nuclear export machinery, NXF1, p15, Rae1 and E1B-AP5, 
of which p15 specifically interacts with the NS1 effector domain (Satterly et al. 
2007). Along with CPSF binding, inhibition of mRNA export is a way for NS1 to 
down-regulate host gene expression. Loss of this inhibition through the use of a 
quinoline carboxylic acid has been shown to cause significant reduction in influenza 
A virus replication (Zhang et al. 2012). Thus, interaction with the mRNA nuclear 
export machinery may play a role in the observed NES mutant phenotypes.  
 
NS1 activation of PI3K through binding to the inter-SH2 domain of the p85β 
subunit of PI3K is also connected to the NES region. Li et al. indicated the NS1 
amino acid region 137-142 in NS1-p85β interaction and showed interference of the 
interaction by mutation of the NS1 amino acids 141 and 142 (Li et al. 2008). In 
other studies the mutation of NS1 amino acid 138 has been shown to influence the 
NS1-p85β interaction (Fan et al. 2013, Li et al. 2012). A structural study of the p85β 
iSH2-NS1 –complex showed that the entire 142-148 amino acid region lies at the 
NS1-p85β interface and discussed the possibility of salt bridge formation between 
p85β and residues of the NES region (Hale et al. 2010). Moreover, several studies 
have shown reductions in growth and IFN antagonistic properties associated with 
impairment of the NS1-p85β interaction (Hale et al. 2006, Shin et al. 2007, Hale et 
al. 2010), indicating that loss of p85β binding could explain the observed NES 
mutant phenotypes. The clear reduction in phosphorylation of Akt by mutant viruses 
(L144A, L146A) and (A149V) suggests that PI3K activation is indeed impaired in 
these viruses (I, Fig. 6C). 
 
Finally, consideration should be given to the possibility of changes in NS1 
conformation caused by the NES mutations. NS1 is a very multifunctional protein 
and has been shown to adopt several different quaternary conformations to facilitate 
different interactions (Carrillo et al. 2014, Das et al. 2008, Hale et al. 2010). Any 
mutation that restricts NS1 conformational plasticity might knock out functions 
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dependent on a given conformation. At least the linker region has been suggested to 
play an important role in NS1 conformational plasticity (Carrillo et al. 2014), but 
additional sites may also exist. Interestingly, mutations introduced within the NS1 
linker region have been shown to result in a phenotype remarkably similar to the one 
exhibited by the mutant virus (L144A, L146A) (Li, Noah & Noah 2011). The impact 
of a given protein region for conformational stability is difficult to speculate, but one 
approach has been to combine structural information with estimations of the degree 
of conservation of different regions (Darapaneni, Prabhaker & Kukol 2009). 
Darapaneni et al. described several conserved sites of probable structural importance 
on NS1 and suggested that both leucine 144 and alanine 149 are involved in 
stabilizing NS1 structure. Quantitation of NS1 expression during infection showed 
that NS1 (L144A, L146A) expression was reduced approximately 50% compared to 
wild-type NS1 expression (I, Fig. S3). A reduction of 50% in NS1 amount is 
unlikely to cause defects in influenza A virus replication, because even reductions as 
large as 90% have been found to be insufficient for influencing replication (Chua et 
al. 2013). However, such a reduction does suggest some structural defect, and thus 
influence on NS1 conformation by the NES mutations cannot be ruled out. 
 
4.2 Mechanisms of NS1 intracellular localization 
Because of its importance for the function of many viral proteins, nucleo-
cytoplasmic transport has been suggested as a target for antiviral drug development 
(Caly, Wagstaff & Jans 2012). In order for that approach to work, it is essential to 
understand how viral proteins are shuttling between the nucleus and cytoplasm. NS1 
nuclear import has been well studied and found to be facilitated by importin α 
(Melen et al. 2007). However, when this work was started no studies on the 
mechanism of NS1 nuclear export had been done. Also, interaction of NS1 with host 
nucleolar proteins remained unresolved. In the second part of our work we focused 
on the mechanisms of NS1 nuclear export and the interaction of NS1 with the host 
cell nucleolus.  
 
The NES of influenza A virus NS1 protein is a classical hydrophobic leucine-rich 
nuclear export signal, which usually facilitates transport across the nuclear 
membrane through interaction with the nuclear transport receptor CRM1 (Fornerod 
et al. 1997, Fukuda et al. 1997, Ossareh-Nazari, Bachelerie & Dargemont 1997). 
There is evidence however, that NS1 is exported independently of CRM1 (Han et al. 
2010). Han et al. used transfected NS1 constructs and FRET techniques to show that 
NS1 did not interact with CRM1. These results should be interpreted with caution 
however, since the NS1 NES has been reported to remain inactive in transfected 
cells (Li, Yamakita & Krug 1998). Therefore NS1 CRM1 dependence remains to be 
verified during an actual infection. To that end we infected A549 cells with 
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A/Udorn/72 wild-type virus in the presence or absence of Leptomycin B (LMB), a 
known inhibitor of CRM1 (Nishi et al. 1994). Analysis of NS1 localization showed 
no significant differences between treated and untreated cells (I, Fig. 7), indicating 
that NS1 export is independent of CRM1 or possibly that NS1 can be exported by 
several alternative mechanisms. By what mechanism is NS1 exported then? 
Examples of leucine rich hydrophobic nuclear export signals functioning 
independently of CRM1 include protein kinase inhibitor (PKI) and glucocorticoid 
receptor, which are both exported by the Ca2+-binding protein calreticulin through a 
mechanism similar to CRM1-mediated export (Holaska et al. 2001, Holaska et al. 
2002). Some effort was put into trying to knock down calreticulin protein expression 
by siRNA to check for a possible impact on NS1 export, but sufficient silencing was 
not achieved (data not shown). Another possibility is the export of NS1 through the 
NXF1-p15 pathway, which is involved in mRNA transport. Some viral proteins, 
including Epstein-Barr virus EB2 and hepatitis B virus core protein, have been 
shown to rely on the NXF1-p15 pathway for nuclear export (Juillard et al. 2009, 
Yang et al. 2014). This is an intriguing possibility for NS1 also and should be 
looked into further, since NS1 has been shown to interact directly with both NXF1 
and p15 (Satterly et al. 2007). 
 
The nucleolus is a dynamic, complex, non-membranous structure within the nucleus 
involved in ribosome biogenesis and a multitude of other functions, including cell 
cycle regulation, signal recognition particle assembly, apoptosis and stress responses 
(Boisvert et al. 2007). The nucleolus is also a target for many viral proteins either as 
a means to perturb some of the functions mediated by the nucleolus or to recruit 
nucleolar proteins for the benefit of virus infection (Hiscox 2007). Some examples 
include West Nile virus capsid protein, which activates p53-mediated apoptosis 
(Yang et al. 2008) and hepatitis C virus Core protein, which targets several nucleolar 
proteins to induce apoptosis and regulate transcriptional pathways (Kao, Chen & 
Lee 2004, Otsuka et al. 2000). The function of influenza A NS1 in the nucleolus has 
not been studied much and thus remains unclear.  
 
Unlike NLS and NES signals, which must mediate translocation across a membrane, 
nucleolar localization signals are more like retention signals, mediating nucleolar 
localization by binding to a nucleolar protein (Emmott, Hiscox 2009). Thus, to 
understand NS1 nucleolar localization mechanics is to understand which nucleolar 
proteins are bound by NS1. In our second study we concentrated on defining which 
nucleolar proteins are bound by NS1. To that end we created expression plasmids 
coding for either full-length or fragmental NS1 proteins from different strains fused 
to either GFP or GST (II, Fig. 2 and 3). Immunofluorescence analysis confirmed our 
previous observation (Melen et al. 2007) of NS1 C-terminus and specifically the 
NoLS sequence directing NS1 nucleolar localization (II, Fig. 2). NS1 was also found 
to colocalize with the major nucleolar proteins nucleolin, B23 and fibrillarin (II, Fig. 
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5). However, GST pull-down assays using in vitro –translated nucleolin, B23 and 
fibrillarin proved direct interactions with only nucleolin and fibrillarin (II, Fig. 4). 
NS1 proteins from strains lacking the C-terminal NoLS still exhibited binding to 
nucleolar proteins and/or nucleolar localization to some extent, but the 
interaction/localization was much weaker than with A/Udorn/72 NS1, which 
contains a functional NoLS (II, Fig. 1, 2, 3 and 4). Interestingly, the N-terminal 1-73 
amino acid fragment of A/Udorn/72 also showed binding to in vitro –translated 
nucleolin and fibrillarin, albeit to a lesser degree than the C-terminal fragment (II, 
Fig. 4). This binding was abolished upon mutating NS1 amino acids R38 and K41, 
which are critical for NLS1 and RNA-binding functions, indicating that RNA-
binding might be involved in the interaction (II, Fig. 4). Since nucleolin and 
fibrillarin are both RNA-binding proteins, the observed interaction with NS1 RNA-
binding domain might not be a true interaction, but rather could represent both NS1 
and nucleolin/fibrillarin binding to the same RNA molecule and thus clumping 
together in the pull-down assays. Such a dependency on RNA for protein-protein 
interaction in a similar setting has been shown for fibrillarin binding of porcine 
reproductive and respiratory syndrome virus N protein (Yoo et al. 2003). RNAse 
treatment of the samples would have clarified this issue, but unfortunately it did not 
occur to us at the time of experimentation. Our results are consistent with a previous 
study on nucleolin NS1 binding by Murayama and co-workers, however they failed 
to observe nucleolin binding by the NS1 C-terminus (Murayama et al. 2007).  
    
Volmer and coworkers studied the nucleolar localization of NS1 proteins from 
various avian and human strains in different cell types, including human, murine and 
avian cells (Volmer et al. 2010). Similarly to our results, nucleolar localization in 
human and murine cells required a functional C-terminal NoLS, but in avian cells all 
the tested NS1 proteins localized to the nucleolus despite the lack of a C-terminal 
NoLS in most of them (Volmer et al. 2010). Volmer and coworkers suggested a 
conserved NS1 “avian NoLS”, but did not speculate on the specific sequence of such 
a functional element. In the light of our own results and those by Murayama and 
coworkers, it is tempting to speculate that perhaps the NS1 NLS1 also functions as a 
NoLS in avian cells by binding to avian nucleolar proteins, but is only partially 
effective in binding mammalian ones, thus leading to the observed weak interactions 
in binding experiments. Additional binding experiments using avian nucleolar 
proteins could yield interesting results. 
 
Since NS1 localizes to the nucleolus, there should also be a specific nucleolar 
function for NS1. Obvious candidates for functional significance are the NS1 
interaction partners nucleolin and fibrillarin. Nucleolin is an abundant and 
multifunctional protein found mostly in the nucleolus, but also in the nucleoplasm, 
cytoplasm and cell membrane (Abdelmohsen, Gorospe 2012). The main function of 
nucleolin is considered to be ribosome biogenesis, where it is involved in several 
Results and discussion 
 
 48  
 
early steps, but nucleolin is also known to play a part in DNA metabolism, 
transcription and nucleo-cytoplasmic transport (Abdelmohsen, Gorospe 2012). 
Fibrillarin is a small nucleolar ribonucleoprotein functioning in ribosomal RNA 
modification during processing of pre-rRNA (Reichow et al. 2007). Interactions 
with nucleolin by other viral proteins are known to promote viral replication, 
stimulate translation and facilitate virion entry into the host cell (Hirano et al. 2003, 
Izumi et al. 2001, Su et al. 2015). The porcine reproductive and respiratory 
syndrome virus N protein has been shown to bind fibrillarin, but the functional 
significance of this interaction is unclear (Yoo et al. 2003). Nucleolin and fibrillarin 
do not have any recognized roles in influenza A virus replication, so it is difficult to 
speculate on their possible functional significance without further experiments. 
 
One possible explanation for NS1 nucleolar localization is the inhibition of tumor 
suppressor p53, which is a major factor in cell cycle regulation and apoptosis. p53 is 
transiently expressed in human cells and its levels are normally kept low by 
ubiquitination-directed proteolysis (Lee, Gu 2010). Besides ubiquitination, p53 is 
also a target for acetylation, methylation, phosphorylation, neddylation and 
sumoylation, leading to a complex regulation system which enables responses to 
various kinds of cellular stress (Lee, Gu 2010). The nucleolus is involved in p53 
regulation by harboring proteins that inhibit the function of E3 ubiquitin ligase 
MDM2, which is considered the major inducer of p53 proteolysis through 
ubiquitination (James et al. 2014). Also, p53 reportedly accumulates in the nucleolus 
after certain kinds of cellular stress (Klibanov, O'Hagan & Ljungman 2001). 
Influenza A virus NS1 has been shown to interact directly with p53and inhibit its 
function (Terrier et al. 2013, Wang et al. 2010). This contradicts with reports on p53 
activation during influenza A virus infection (Turpin et al. 2005, Zhirnov, Klenk 
2007), which is explained by another influenza A virus protein, NP, acting as an 
activator of p53 (Wang et al. 2012). NP also localizes to the nucleolus and causes an 
impairment of the MDM2-p53 interaction, thus increasing the stability of p53 
(Wang et al. 2012). This sets up an interesting regulatory mechanism, where NS1 
and NP exert competing pressures towards p53, possibly resulting in temporal 
regulation of p53 activity. This view is supported by a study on p53 activation 
during influenza A infection, where p53 was found to follow a biphasic pattern, 
activating first at an early stage of infection and then again at the late stage of 
infection (Shen et al. 2009). It is however doubtful whether nucleolar localization 
would be essential for p53 interaction, since p53 mostly resides in the nucleoplasm. 
 
Another clue to the nucleolar function of NS1 might be the similarity with the HIV-
1 Rev protein. In transfected HuH7 cells NS1 was found to colocalize with Rev and 
overexpression of Rev even caused displacement of NS1 from the nucleolus (II, Fig. 
6), indicating that NS1 and Rev might bind to the same nucleolar structures. Rev is 
known to bind to B23 (Fankhauser et al. 1991), and while NS1 did not show binding 
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to in vitro translated B23 (II, Fig. 4), there was some evidence of NS1 induced 
displacement of B23 from the nucleolus to the nucleoplasm in infected A549 cells 
(II, Fig. 5B). B23 is involved in a wide variety of different cellular processes, 
including cell cycle regulation, ribosome biogenesis and apoptosis. B23 also 
regulates p53 stability by interacting with ARF, MDM2 and p53. ARF, a nucleolar 
inhibitor of MDM2, is stabilized by B23 interaction, but the interaction also prevents 
ARF from interacting with MDM2 (Korgaonkar et al. 2005). B23-MDM2 
interaction causes inhibition of MDM2 (Kurki et al. 2004), while p53 is stabilized 
by B23 (Colombo et al. 2002). The nucleolar B23 thus normally inhibits ARF, 
allowing MDM2 to keep p53 levels low, but nucleolar disruption in response to 
various stress events causes displacement of B23 to the nucleoplasm leading to 
inhibition of MDM2, stabilization of p53 and apoptosis (Rubbi, Milner 2003). The 
idea of B23 displacement by NS1 affecting p53 regulation during influenza A 
infection is an intriguing one, but the observed displacement effect is so small that it 
is unlikely to have a large impact (II, Fig. 5). 
 
Besides ribosome biogenesis, the nucleolus is also a site for RNA editing. ADAR1 
and ADAR2 are RNA editing enzymes that normally shuttle in and out of the 
nucleolus (Desterro et al. 2003). Their substrates are long dsRNA duplexes and pre-
mRNA transcripts, where they function to deaminate adenosine to inosine. Such a 
function would not be expected to have a role during influenza A virus infection, but 
interestingly NS1 was found to interact with ADAR1 in a yeast two-hybrid 
screening assay (de Chassey et al. 2013). Moreover, ADAR1 was found to be a pro-
viral host factor and influenza A virus infection caused colocalization of ADAR1 
with NS1 inside the nucleolus (de Chassey et al. 2013). NS1 interaction also caused 
enhancement of ADAR1 editing activity (de Chassey et al. 2013). It is unclear what 
benefit this might incur for influenza A virus infection, but ADAR1 interaction with 
NS1 clearly happens in the nucleoli, and thus it is an example of an interaction that 
might be enforced by the NoLS-directed nucleolar localization. 
 
The NS1 NLS2/NoLS is strain specific, appearing only in human strains isolated 
between 1950 and 1987 (Melen et al. 2007). It is generated by a single nucleotide 
mutation changing a stop codon into an arginine codon and causing a seven amino 
acid extension to the NS1 protein. There must be a beneficial effect for influenza A 
virus infection conferred by the mutation, since it evolved and lasted for so long, but 
then again the benefit is probably a small one since it was lost in 1987. The impact 
of the extension on viral replication was studied by Lohrmann and coworkers and 
found to be very small (Lohrmann et al. 2013). Using recombinant viruses, 
Lohrmann and coworkers did not find any differences in replication kinetics or 
interferon antagonistic properties in cell lines between the wild-type and 
recombinant viruses (Lohrmann et al. 2013). A slight growth benefit in mice and in 
competition experiments in cell lines were the only observed differences (Lohrmann 
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et al. 2013), indicating a minor functional significance for NS1 nucleolar 
localization. 
4.3 Assessing susceptibility of human monocyte-derived 
macrophages and dendritic cells for MERS-CoV infection 
In order to successfully invade the host and start an infection, respiratory viruses 
entering the lungs have to overcome several obstacles, including mechanical 
barriers, cytokine production by the airway epithelial cells and the actions of the 
cells of the innate immune system present in the lung (Whitsett, Alenghat 2015). 
Lung resident macrophages and dendritic cells play a critical role in infection 
control and their interaction with invading respiratory viruses can have strong 
consequences for the outcome of an infection (Kopf, Schneider & Nobs 2015). 
Understanding this interaction is important for understanding the pathogenesis of a 
respiratory virus. In the final part of our work we concentrated on the interaction of 
the novel coronavirus MERS-CoV with human monocyte-derived macrophages and 
dendritic cells (MDDCs). 
 
Many respiratory viruses are known to infect and replicate in macrophages or 
dendritic cells. Some examples include influenza A virus (Rodgers, Mims 1982, 
Bender et al. 1998), rhinovirus (Laza-Stanca et al. 2006) and also human 
coronaviruses OC43 and 229E (Collins 1998, Funk et al. 2012). Besides the obvious 
benefit of replication, some viruses use DC infection as a means to invade further 
into the body by taking advantage of DC migration through the lymphatic system 
(Rinaldo, Piazza 2004). Our laboratory has previously shown that SARS-CoV is 
unable to productively replicate in human monocyte-derived macrophages and 
MDDCs (Ziegler et al. 2005). In study III of the present thesis work we analyzed the 
replication and induction of innate immune responses by MERS-CoV in human 
monocyte-derived macrophages and MDDCs and compared the responses to those 
induced by SARS-CoV. Assays measuring replication at the RNA level and at the 
level of viable virion production both showed no evidence of efficient MERS-CoV 
or SARS-CoV replication in either cell type, with no or only a very weak increase in 
viral RNA levels and a steady decline in viral supernatant titers throughout the 
infection (III, Fig. 1). A similar infection of susceptible Vero E6 and Calu-3 cell 
lines proved the viability of our virus stocks and experimental setting (III, Fig. 2). 
As still further confirmation, Western blot analysis of macrophage and MDDC cell 
lysates showed no increase in viral N-protein expression during infection (III, Fig. 
3). qRT-PCR measurement of IFN-β, IFN-λ1, CXCL10, TNF-α and MxA mRNA 
levels showed mostly similar mRNA production between virus-infected 
macrophages and MDDCs, but a clear difference between MERS-CoV and SARS-
CoV was observed (III, Fig. 4 & 5). Whereas SARS-CoV only induced a slight 
increase in IFN-λ1 mRNA expression in MDDCs, significant inductions of CXCL10 
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and MxA as well as some induction of IFN-β and IFN-λ1 was seen in response to 
MERS-CoV infection (III, Fig. 4 & 5). Curiously, this difference between the 
viruses was not evident in Calu-3 cells, where both viruses induced a strong 
response (III, Fig. 6). As a control, influenza A (A/Beijing/89) infection was 
included in the MDDC experiments to estimate the MERS-CoV response in the 
context of a known strong inducer of innate immune responses. MERS-CoV –
induced cytokine responses were rather weak in comparison to A/Beijing/89 virus, 
which induced approximately 100- to 1000-fold higher levels as compared to 
MERS-CoV (III, Fig. 5), but that should also be expected since no efficient 
replication was observed for MERS-CoV in MDDCs (III, Fig. 1). MxA expression, 
however, reached levels comparable to those induced by A/Beijing/89 virus (III, Fig. 
5), indicating a relatively strong innate immune response against MERS-CoV.  
 
Efficient mRNA production does not always correspond to efficient protein 
translation and/or secretion. Therefore, to further characterize the innate immune 
responses induced by MERS-CoV, we performed ELISA analysis of cell culture 
supernatants from the macrophage, MDDC and Calu-3 infection experiments to 
quantitate the production of IFN-λ1, TNF-α and CXCL10. No measurable amounts 
of IFN-λ1 or TNF-α were detected (data not shown), suggesting inefficient 
translation or secretion despite the observed increases in mRNA production. This 
was true even for Calu-3 cells, where up to a 1000-fold increase in IFN-λ1 mRNA 
expression in relation to uninfected cells was measured, highlighting the importance 
of confirming gene expression data at the protein level. CXCL10 concentrations of 
up to 10000 pg/ml were measured in supernatants of MERS-CoV infected 
macrophages and MDDCs, in contrast to no detectable CXCL10 in response to 
SARS-CoV infection (III, Fig. 7). A notable feature were the striking differences 
between donors, as half of the analyzed donors gave strong CXCL10 responses 
against MERS-CoV, while the other half gave no response at all (III, Fig. 7). In 
Calu-3 cells, SARS-CoV was a better inducer of CXCL10 than MERS-CoV (III, 
Fig. 7). Western blot analysis of MxA protein levels in infected macrophages and 
MDDCs showed that the observed increases in mRNA expression also resulted in 
increased MxA protein production (III, Fig. 3). In MERS-CoV infected 
macrophages strong MxA bands were seen from 24 h post infection onwards, 
whereas in MDDCs no production was detected until the 72 h time point (III, Fig. 
3). SARS-CoV infection was also found to result in MxA production in 
macrophages at the 24 h time point (III, Fig. 3). In an effort to evaluate the 
biological significance of the observed cytokine production, we used UV-inactivated 
supernatants from the infection experiments to prime A549 cells followed by an 
infection with A/Beijing/89 virus. Measurement of influenza A virus M1 mRNA 
expression levels at 6 h post infection showed that supernatants from MERS-CoV 
infected macrophages and MDDCs and A/Beijing/89 infected MDDCs were the 
only ones to result in significant reduction of M1 expression levels (III, Fig. S1). All 
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this indicates that there is a significant difference in blocking host cell innate 
immune responses between SARS-CoV and MERS-CoV. 
 
Determinants of SARS-CoV virulence have been well studied during the past 10 
years and as a result the roles of several SARS-CoV proteins in blocking host cell 
innate immune responses have been elucidated (DeDiego et al. 2014). Since all 
coronaviruses share the polyprotein encoding 1a/1b gene, the different host cell 
responses to SARS-CoV and MERS-CoV are probably due to different 
compositions of accessory genes. For SARS-CoV, the accessory proteins Orf3a, 
Orf3b and Orf6 have all been shown to inhibit interferon signaling by different 
mechanisms (Kopecky-Bromberg et al. 2007, Minakshi et al. 2009, Spiegel et al. 
2005, Frieman et al. 2007). In addition, the structural proteins M and N are known to 
inhibit type I interferon production (Kopecky-Bromberg et al. 2007, Siu et al. 2009). 
For MERS-CoV, many functions of the accessory proteins still remain unclear, but a 
few recent studies have identified the accessory proteins Orf4a, Orf4b and Orf5 as 
well as the structural and non-structural M and nsp3 proteins as IFN antagonists 
(Yang et al. 2013, Niemeyer et al. 2013, Matthews et al. 2014, Yang et al. 2014). 
The mechanisms of function have been solved for Orf4a and Orf4b, which elicit 
their inhibitory effects through suppression of PACT-induced activation of RIG-I 
(Siu et al. 2014) and through interaction with TBK1 and IKKε and inhibition of 
IRF3 and IRF7 (Yang et al. 2015). These differing sets of antagonistic proteins are 
likely the major reason for the observed variation in host response, but other factors 
might be involved as well. 
 
Besides harboring different sets of IFN antagonistic proteins, another major 
difference between MERS-CoV and SARS-CoV is different receptor usage. ACE2, 
the receptor of SARS-CoV (Li et al. 2003), is widely expressed in many different 
tissues (Hamming et al. 2004), but reportedly not in monocytes or MDDCs (Law et 
al. 2005). SARS-CoV has been shown to bind to DC-SIGN, which is expressed in 
DCs, but binding to DC-SIGN does not facilitate entry inside the cell (Yang et al. 
2004). Thus, the lack of a suitable receptor might be a factor both in the lack of 
SARS-CoV replication and in the lack of a SARS-CoV induced host response in 
macrophages and MDDCs. DPP4, the receptor for MERS-CoV (Raj et al. 2013), is 
also expressed in many different tissues and reportedly also in monocyte-derived 
macrophages and MDDCs (Lambeir et al. 2003, Zhong et al. 2013). We verified the 
expression of DPP4 in the cells used in our experiments by qRT-PCR and Western 
blot and found all of them to express DPP4, although there were differences in the 
expression levels between different cell types (III, Fig. 8). The lack of a receptor is 
therefore not an explanation for the poor replication of MERS-CoV in macrophages 
and MDDCs. However, the lack of N protein expression and viral RNA production 
in MERS-CoV infected macrophages and MDDCs (III, Fig. 1 & 3) suggests an early 
block in the viral replication cycle. Besides receptor availability, an alternative 
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reason for failed virion internalization might be deficient viral spike protein 
cleavage. The coronavirus S protein is a class I viral fusion protein and it requires 
cleavage for efficient internalization into a host cell (Bosch et al. 2003). The activity 
of host cell surface proteases is essential for this cleavage and thus the complement 
of cell surface proteases should be considered a factor affecting coronavirus host cell 
tropism (Millet, Whittaker 2015). MERS-CoV has been shown to utilize several 
different host cell proteases for S protein cleavage, including TMPRSS2 (Gierer et 
al. 2013), cathepsin L (Shirato, Kawase & Matsuyama 2013), furin (Burkard et al. 
2014, Millet, Whittaker 2014) and DESC1 and MSPL (Zmora et al. 2014). It is 
unclear whether any of these can be considered the “primary” protease used by 
MERS-CoV for S protein cleavage, but at least the overexpression of TMPRSS2 and 
furin has been shown to increase host cell susceptibility to MERS-CoV infection 
(Shirato, Kawase & Matsuyama 2013, Millet, Whittaker 2014). It is likely that 
MERS-CoV can utilize different proteases in different cell types (Shirato, Kawase & 
Matsuyama 2013). Studies on the specific content of cell surface proteases on 
monocyte-derived macrophages and MDDCs are not available, but some studies on 
the tissue distribution of TMPRSS2 have been made. Vaarala and coworkers 
reported the absence of TMPRSS2 expression in peripheral leukocytes (Vaarala et 
al. 2001), while Bertram and coworkers found TMPRSS2 expression in alveolar 
macrophages and some other leukocytes (Bertram et al. 2012). An additional 
infection experiment with added trypsin or a similar serine protease would have 
helped clarify the issue of whether cell surface protease composition plays a role in 
MERS-CoV infection of monocyte-derived macrophages and MDDCs. 
 
A notable aspect when dealing with primary human macrophages and dendritic cells 
is the possibility of large variations between individual donors. Responses to 
infection can have significant differences between donors and even susceptibility to 
infection can vary with some viruses (Bol et al. 2009). Such variability was evident 
in our experiments also, as striking differences were observed in CXCL10 
production between donors (III, Fig. 7). Interestingly, comparison of MERS patients 
has revealed similar large variations between patients in their immune response to 
MERS-CoV (Faure et al. 2014). Clearly, individual attributes can have a large 
impact on the course of MERS-CoV infection and deciphering these features will 
help us better understand the pathogenesis of MERS-CoV. Conflicting reports have 
also been published on MERS-CoV replication in macrophages and MDDCs. Like 
us, Scheuplein and coworkers found monocyte-derived macrophages and MDDCs 
unpermissive for MERS-CoV replication (Scheuplein et al. 2015), while Chu and 
Zhou and their coworkers reported productive infection in both macrophages and 
MDDCs (Chu et al. 2014, Zhou et al. 2013). Whether this represents donor 
variability or differences in experimental settings is unclear, but our results push the 
consensus towards monocyte-derived macrophages and MDDCs being 
unsusceptible towards MERS-CoV infection. 
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5 Conclusions and future 
prospects 
The influenza A virus NS1 is an incredibly multifunctional protein, having a 
multitude of different interactions with host cell components both in the nucleus and 
in the cytoplasm. Temporal and spatial regulation of the many functions of NS1 are 
still poorly understood, but intracellular localization undoubtedly plays a significant 
role in the regulation. Accordingly, nuclear localization of NS1 has been shown to 
be crucial for inhibiting the production of IFN-β mRNA (Min, Krug 2006, Donelan, 
Basler & Garcia-Sastre 2003). Despite being described over 15 years ago, the 
significance of the NS1 nuclear export signal for influenza A virus infection had not 
been analyzed. Also the mechanisms involved in NS1 nuclear export and in 
nucleolar localization remained poorly described.  
 
In the present thesis work, we set out to investigate the mechanisms and impact of 
NS1 nuclear export and nucleolar localization. We found nuclear export of NS1 to 
not only be non-essential for virus infection, but we failed to see any consistent 
effects in growth or IFN antagonistic properties resulting from NS1 nuclear 
retention in mutant viruses harboring abolished NES signals. This was surprising 
considering the conserved nature of the NS1 NES. We did see increased IFN 
production and diminished growth properties resulting from certain NES mutations, 
but we had to assign these effects to something aside from localization since these 
phenotypes were not shared by all mutant viruses with inactivated NES signals. This 
raises additional questions on the possibility of other functions coinciding with the 
NS1 NES. Based on current knowledge, the most plausible explanation for the 
observed phenotypes is the impairment of p85β interaction, but other possibilities 
are sure to exist and should be looked into further. Supporting evidence for the 
disturbance of NS1 activation of PI3K by the NES mutations could be gained by 
additional experiments assessing induction of apoptosis by the mutant viruses. One 
should also bear in mind that these experiments were done in cell lines and therefore 
the results might not be an accurate representation of the situation in living animals. 
An obvious next step would be to conduct animal experiments using virus strains 
suitable for animal infections harboring the same NES mutations. There is already 
evidence showing a reduction in influenza A H5N1 pathogenesis in chickens upon 
introduction of the NS1 A149V mutation (Li et al. 2006). The same mutation does 
not seem to have an impact on virus replication in mammals however (Jiao et al. 
2008), suggesting either strain or host specific variation in the importance of the 
NS1 NES region. 
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In the mechanistic part of our study we were unable to establish the exact 
mechanism of export used by NS1, but our results suggest the independence of NS1 
nuclear export from CRM1. This was also somewhat surprising considering that the 
literature on classical leucine-rich nuclear export signals indicates that a vast 
majority of them mediate nuclear export through interaction with CRM1. Export 
through interaction with calreticulin is one possibility, but unfortunately we were 
unsuccessful in trying to knock down calreticulin in our experimental settings and 
thus cannot speculate further. Perhaps a more interesting alternative is export 
through the NXF1-p15 pathway. NS1 is known to interact with both NXF1 and p15 
and examples from other viruses support the feasibility of this idea. More effort 
should be put into knocking down these host cell proteins with siRNA or other 
methods in order to gain a better understanding of NS1 nuclear export. Another 
direction for future studies is the dynamic analysis of NS1 localization kinetics using 
advanced microscopic methods like fluorescence recovery after photobleaching 
(FRAP) or fluorescence loss in photobleaching (FLIP). Such analysis would answer 
the question whether NS1 NES is only activated at a certain point of infection or 
rather upholds constant shuttling between the nucleus and cytoplasm.   
 
In our second study we were able to elucidate the nucleolar proteins which interact 
with NS1 and thus drive its nucleolar localization. Our results also confirm the C-
terminal NoLS as the NS1 region responsible for nucleolar localization. The 
functional aspect of NS1 nucleolar localization still remains elusive, as the 
recognized interaction partners nucleolin and fibrillarin have not been assigned any 
known roles in influenza A virus replication, but they make good focal points for 
future research aimed at solving the nucleolar function of NS1. Regulation of 
apoptosis through p53 interaction has been previously suggested to be the nucleolar 
function of NS1, but sufficient evidence is lacking to make such a statement. The 
reported interaction of NS1 with ADAR1 is an interesting observation and a good 
target for future studies. 
 
Historically regarded only as a minor threat to public health, the human 
coronaviruses have gained newfound attention upon first the emergence of SARS-
CoV in 2002 and now again with the emergence of MERS-CoV in 2012. While 
considerable effort has been put in elucidating the aspects of MERS-CoV 
pathogenesis, much of it still remains unclear. In the present study we showed that 
infection of human monocyte-derived macrophages and MDDCs with MERS-CoV 
does not result in productive replication. Despite the lack of replication, a significant 
induction of antiviral genes in response to MERS-CoV infection was measured, 
marking a clear difference to SARS-CoV, which barely induced any measurable 
increase in antiviral gene expression. Our results clarify the current consensus on 
MERS-CoV infection of leukocytes, since conflicting reports on macrophage and 
MDDC permissibility to MERS-CoV infection have been published previously. Our 
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observation of large differences in CXCL10 production between donors also 
highlights the impact of individual variation in MERS-CoV response, which is an 
aspect of MERS-CoV infection also reported in patients. Future studies might focus 
on the exact mechanisms that cause the observed differences between MERS-CoV 
and SARS-CoV. 
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